Source: GUIPCAR Group. In: Clinical practice guideline for the management of rheumatoid arthritis. Madrid: Spanish Society of Rheumatology; 2001. 146 p.
Download a printable copy in PDF format: or a text-only version:
Contents
PARTICIPATING INSTITUTIONSRheumatoid arthritis (RA) is a highly prevalent disease in Spain, and its management consumes a large amount of health and social resources. The disease often has serious repercussions on the quality of life of those affected, provoking chronic pain, limitations in the activities of daily living, and work disability. Although there is currently no cure for the disease, its symptoms can be controlled by early detection and the initiation of appropriate treatment. In recent years, however, the appearance of new drugs, new forms of combined treatment, and a plethora of studies on the efficacy of different therapeutic modalities means that the clinician is not always sure which treatment strategy to follow for a particular patient.
Faced with this explosion of new information, it is not surprising that there is large variability in the treatment of patients with RA, which cannot always be explained by characteristics of the disease. Thus, the Spanish Society of Rheumatology (SER), aware of the difficulties involved in making decisions about the management of RA, decided to develop this Clinical Practice Guideline for the Management of Rheumatoid Arthritis in Spain (Guía de Práctica Clínica para el manejo de Artritis Reumatoide en España - GUIPCAR). The aim of the guideline is to help clinicians make decisions about their patients. The guideline recommendations are based on the best available scientific evidence and, when this is lacking, on the work of an expert panel that developed a series of detailed recommendations on the diagnosis, management, and treatment of patients with RA. The recommendations on disease-modifying antirheumatic drugs (DMARDs) are the result of an exhaustive review and synthesis of the published randomized clinical trials meeting strict methodological criteria for these types of studies.
Clinical practice guidelines are one of the most appropriate tools for improving the quality of care and decreasing unnecessary variability in clinical practice. Their objective is to offer systematically developed recommendations to aid the physician and patient in decision making. Although these recommendations aim to include most patients who would present to a physician, there may be particular circumstances in which they do not apply.
With this work, the SER hopes to offer the clinician a practical tool that will prove useful in daily clinical practice. We hope the information included here will be of assistance to physicians, will help improve the quality of care, and, above all, will help patients who suffer from RA. Should this be so, we will have achieved an important objective for the year 2001, designated by the Society as the "Year of Rheumatoid Arthritis."
Armando Laffón Roca
Emilio Martín Mola
This guideline is an initiative of the Spanish Society of Rheumatology. A number of institutions have collaborated in carrying out this initiative:
Spanish Society of Rheumatology (Sociedad Española de Reumatología - SER). The SER promoted the idea for this guideline, chose the research group to develop it, helped select the panel of experts, sponsored its development, and presented the project to the financing organization.
Health Services Research Unit (Unidad de Investigación en Servicios de Salud - UISS). When the SER decided to produce the guideline in late 1998, the Society proposed that it be developed by the UISS. At that time the UISS was a research unit within the Carlos III Health Institute (ISCIII). The UISS began to develop the guideline, but organizational changes in the ISCIII took place at the end of 2000. The UISS then became a private company with the name of TAISS, part of whose research staff came from the UISS.
Ignacio de Mercado Foundation (Fundación Ignacio de Mercado - FIdeM) for research and education in the health services. The FIdeM contracted project personnel who were not on the staff of the UISS.
Advanced Research Techniques in the Health Services (Técnicas Avanzadas de Investigación en Servicios de Salud, S.L. - TAISS). TAISS is a company devoted to producing knowledge to improve decision making in the health sector at the macro (policy) level, as well as at the meso (management) and micro (physician-patient) levels. Its research staff came from the UISS. All the investigators who participated in the project at its inception have continued to work on it.
Novartis. Novartis is the organization that financed the development of this guideline. It also oversaw each project activity and, together with the SER, monitored project tasks to ensure they were carried out in a correct and timely fashion.
Abbott. This English-language version of GUIPCAR was made possible thanks to Abbott, which provided financing for the translation.
The following format is suggested for citation of this guideline:
GUIPCAR Group. Clinical Practice Guideline for the Management of Rheumatoid Arthritis in Spain. Spanish Society of Rheumatology. Madrid, 2001.
The following persons are members of the GUIPCAR Group, which authored this guideline:
1. Principal Investigator
Pablo Lázaro y de Mercado, Director of TAISS. Founder and director of the Health Services Research Unit (UISS) of the Carlos III Health Institute (1993-2000). Vice-Director General of Health and Technological Evaluation of the Ministry of Health and Consumer Affairs (1997-98). University graduate in Medicine (Complutense University of Madrid, 1973). Doctor of Medicine (Autonomous University of Madrid, 1989). Specialist in Internal Medicine and in Respiratory Diseases (1977). Residency in Respiratory Diseases at the 12 de Octubre Hospital in Madrid (1974-77), and associate in Respiratory Diseases at the Ramón y Cajal Hospital in Madrid (1978-86). Master of Business Administration from the IESE (1989). Post-doctoral studies in health policy analysis at the RAND/UCLA Center for Health Policy Analysis, Santa Monica, California (USA), where he helped develop clinical practice guidelines (1990-93). His areas of expertise include research in the health services, socioeconomic evaluation, medical technology evaluation, development of clinical practice guidelines, and development of appropriateness criteria for clinical procedures.
2. Expert Panel
The experts who developed the recommendations in this guideline, listed in alphabetical order, are:
José Luis Andréu Sánchez, rheumatologist, Clínica Puerta de
Hierro, Madrid.
University graduate in Medicine and Surgery
(Autonomous University of Madrid, 1983), specialist in Rheumatology via the MIR
(Puerta de Hierro Clinic, Madrid, 1984-87) and Doctor of Medicine with special
honors (Autonomous University of Madrid, 1990). Has participated in different
research projects related with Immunology at the Center of Molecular Biology
(Professor Martínez-Alonso) and has been a member of various expert groups
(e.g., the Strategic Plan of the Spanish Society of Rheumatology and the
Consensus Conference on the use of biological therapies in rheumatoid arthritis)
sponsored by the Spanish Society of Rheumatology, of which he was Secretary
(1998-2000). Formerly or currently serving on the editorial boards of various
clinical journals such as Annals of the Rheumatic Diseases, Revista Española
de Reumatología and Revista Clínica Española. Has published over 100 book
chapters, 54 articles in national scientific journals, and 30 articles in the
most prestigious international journals such as Nature, Journal of
Experimental Medicine, and Arthritis and Rheumatism. Editor of 8 books. Has
given over 40 post-graduate seminars on different subjects related with his
speciality. Currently works as a rheumatologist at the Puerta de Hierro Clinic
in Madrid, is honorary professor of Rheumatology at the Faculty of Medicine of
the Autonomous University of Madrid and the Hospital for Rheumatic Diseases of
Barcelona, and is President of the Society of Rheumatology of the Community of
Madrid.
Enrique Batlle Gualda, rheumatologist, University Hospital
General of Alicante, Alicante.
University graduate in Medicine and
Surgery by the Autonomous University of Barcelona (1978), specialist in
Rheumatology via the MIR (1984), Doctor of Medicine (University of Alicante,
1992), and University Specialist in Health Economics and Management of Health
and Social Services (University of Alicante, 1993). Trained in epidemiology and
statistics. Experienced as a teacher, evaluator, and advisor for different
agencies, organizations, and research groups. Research experience in brucelar
arthritis and clinical epidemiology in the evaluation of health-related quality
of life, clinical methodology, and clinical trials. Currently associate in the
Rheumatology Section and Secretary of the Clinical Research Ethics Committee of
the General University Hospital of Alicante, and Associate Professor of the
Miguel Hernández University.
Loreto Carmona Ortells, rheumatologist and epidemiologist,
Spanish Society of Rheumatology, Madrid.
University graduate in
Medicine and Surgery (Autonomous University of Madrid, 1990) and specialist in
Rheumatology via the MIR (La Princesa Hospital, Madrid, 1991-94). Carried out
the project "Clinical Epidemiology and Application to the Study of Rheumatic
Diseases" (FIS BAE grant 96/5485 and 97/5090) in the Arthritis Research Group
(directed by Edward Yelin) and the Departments of Rheumatology and Epidemiology
and Biostatistics of the University of California in San Francisco. Has worked
in the Spanish Medicines Agency (grant FC1 1999- 2000) as technical evaluator
for various recently developed drugs in rheumatology. Coordinator since 1998 for
various epidemiological projects of the Spanish Society of Rheumatology.
Currently contracted as investigator of the Health Research Fund in the Research
Unit of La Princesa Hospital to develop a line of Research in Rheumatic Diseases
and coordinate the installation of a Cochrane Centre in Madrid for the diffusion
of Evidence-Based Medicine.
Federico Díaz González, rheumatologist, University Hospital
of the Canary Islands, Santa Cruz de Tenerife.
University graduate
in Medicine and Surgery (La Laguna University, 1986), specialist in Rheumatology
via the MIR (La Princesa Hospital, 1991), and Doctor of Medicine from the
Autonomous University of Madrid (1994). Post-doctoral training under grants from
the Ministry of Health and the Spanish Ministry of Education and Science at the
Laboratory of Dr. Mark H. Ginsberg in the Department of Vascular Biology of the
Scripps Research Institute, La Jolla, California. Has published 28 articles in
Spanish and international journals, has authored 2 book chapters and has wide
experience in research. Formerly, specialist in the Rheumatology Department of
La Princesa Hospital of Madrid, and currently occupies the same position in the
University Hospital of the Canary Islands.
Juan José Domínguez Reboiras, orthopedist, La Paz University
Hospital, Madrid.
University graduate in Medicine and Surgery
by the Santiago de Compostela University (1968); Doctor of Medicine and Surgery
from the Autonomous University of Madrid (1974); specialist in Orthopedic
Surgery and Traumatology, in Physical Education and Sports Medicine and in
Occupational Medicine, and Advanced Degree in the Management of Health
Institutions. Tenured Professor in Anatomy and Physiology in the La Paz
University School of Nursing. Formerly, Chief of the Orthopedic Surgery and
Traumatology Department in the Xeral Cies Hospital of Vigo. Currently, Chief of
the Shoulder and Elbow Diseases Unit in the La Paz University Hospital of
Madrid.
Ángel Elena Ibáñez, rheumatologist, San Millán-San Pedro
Hospital, Logroño.
University graduate in Medicine and Surgery
(Autonomous University of Madrid 1979), specialist in Rheumatology via the MIR
(Ramón y Cajal Hospital, Madrid, 1980-1984), and Doctor in Medicine and Surgery
(Autonomous University of Madrid, 1994). Area specialist of the Rheumatology
Section, San Millán-San Pedro Hospital of La Rioja, since 1987. Degree in
Clinical Research (Autonomous University of Madrid, 1997 and National School of
Health, 1999). Formerly responsible for the Clinical-Epidemiological Research
Unit of La Rioja from 1995 to 1999. Currently working in the Rheumatology
Section of the San Millán-San Pedro Hospital of La Rioja, Logroño.
Juan Gómez-Reino Carnota, rheumatologist, University
Clinical Hospital, Santiago de Compostela.
Residency in Medicine and
Fellowship in Rheumatology at the State University of New York at Stony Brook
(USA). Previously Chief of Section of Rheumatology and Director of the Research
Centre of the 12 de Octubre University Hospital of Madrid. Formerly responsible
for the Area of Biomedicine at the National Agency of Planning and Evaluation
(ANEP) and member of evaluation committees for national and international
research. Has published numerous articles in speciality journals in the area of
autoimmune diseases and inflammation. Currently, Chief of the Rheumatology
Department in the Santiago University Clinical Hospital.
Agustún Gómez de la Cámara, epidemiologist, Research Unit,
12 de Octubre Hospital, Madrid.
Doctor in Medicine and Surgery from
the Autonomous University of Madrid. Currently, Chief of the Clinical
Epidemiology Unit of the Research Unit in the 12 de Octubre Hospital. His
training in clinical epidemiology was received, among other centres, at the
Houston Medical Center, University of Texas (USA). Has worked mainly in teaching
and research in the Health Research Fund, Carlos III Health Institute, and 12 de
Octubre Hospital in diagnostic, prognostic, and therapeutic research areas from
the perspective of clinical epidemiology. Actively promotes the use and
development of Evidence-Based Medicine and has translated its basic texts.
Technical advisor to the Health Research Fund and ANEP, and member of the
Spanish Medicines Agency as advisor to the Committee on Drug Safety.
Nuria Guañabens Gay, rheumatologist, Clinical and Provincial
Hospital, Barcelona.
University graduate in Medicine and Surgery
(1978), specialist in Rheumatology (Clinical Hospital, Barcelona, 1979-1984),
and Doctor of Medicine (University of Barcelona, 1987). Responsible for the Bone
Metabolic Disease Team of the Agust Pi I Sunyer Biomedical Research Institute
(IDIBAPS), Clinical Hospital, Barcelona. Currently, medical rheumatology adviser
at the Clinical Hospital and Associate Professor of Medicine of the University
of Barcelona.
César Hernández García, rheumatologist, San Carlos Clinical
Hospital, Madrid.
University graduate in Medicine and Surgery
(Complutense University of Madrid, 1987), Doctor of Medicine (Complutense
University of Madrid, 1996, special honors), and specialist in Rheumatology via
the MIR (San Carlos Clinical Hospital, Madrid, 1988-91). Visiting Fellow at the
Division of Arthritis and Rheumatism, Oregon Health Sciences University. FIS
fellow (1992-94) at the San Carlos Clinical Hospital, Madrid, and Area
Specialist in the Rheumatology Department of that hospital since 1994. Current
major research area is rheumatoid arthritis, involving both clinical research
and health services projects.
Ma Victoria Irigoyen Oyarzábal, rheumatologist,
Carlos Haya General Hospital, Málaga.
University graduate in
Medicine and Surgery (University of Malaga, 1979) and specialist in Rheumatology
via the MIR (Ramón y Cajal Hospital, Madrid 1981-1984). One year of
specialization via the MIR in Anesthesiology (Carlos Haya Hospital, Malaga
1980). Area specialist in Rheumatology (Hospital of Navarra, Pamplona 1987-1992)
and area specialist in Rheumatology (Carlos Haya Hospital, Malaga, Connective
Tissue Diseases Unit, from 1992 to present).
José Luis Marenco de la Fuente, rheumatologist, Hospital
Universitario de Valme, Sevilla.
University graduate in Medicine and
Surgery (University of Sevilla,1974-80), specialist in Rheumatology via the MIR
(Puerto de Hierro Clinic, Autonomous University of Madrid, 1981-84). Doctorate
cum laude in 1986 for the thesis "Synoviorthesis with yttrium-90 in
knees. Long-term results" (directed by Professor Noguera Hernando). Responsible
for the creation of the Rheumatology Section in the Hospitals of Jerez (1987-91)
and Valme of Sevilla (1992) and Chief of Rheumatology Section in the latter
hospital since 1994. Associate Professor of Rheumatology in the Faculty of
Medicine of Sevilla.
Víctor Manuel Martínez Taboada, rheumatologist, Marqués de
Valdecilla University Hospital, Santander.
University graduate in
Medicine and Surgery (University of Zaragoza, 1988) and specialist in
Rheumatology via the MIR (Marqués de Valdecilla University Hospital, Santander,
1992). Completed clinical and research training in the Lupus Research Unit (The
Rayne Institute, St. Thomas Hospital) in London (UK) and in the Rheumatology
Research Unit (Mayo Clinic) of Rochester, Minnesota (USA). Doctor of Medicine
from the University of Cantabria (1998). Since 1994, associate physician of the
Rheumatology Department at the Marqués de Valdecilla University Hospital in
Santander.
Cristina Riera Riezu, rehabilitation therapist, Germans
Trias i Pujol Hospital of Badalona, Barcelona.
University graduate
in Medicine and Surgery (Central University of Barcelona, 1983), specialist in
Physical Therapy and Rehabilitation via the MIR (Germans Trias i Pujol
University Hospital, 1989), and Doctor of Medicine (Autonomous University of
Barcelona, 2000). Member of the Medical Commission of the International
Para-Olympics Committee and of the Catalan and Spanish Sports Federations for
the Physically Handicapped. Member of the Catalan Society of Rheumatology;
received first prize from the Catalan Society of Rehabilitation Therapy for her
work "Rehabilitation therapy in rheumatoid arthritis: protocol for action." Has
published 12 articles in national journals and 8 in international journals, in
addition to 93 conference contributions. Worked as associate physician for the
Department of Rehabilitation Therapy at the General Hospital of Cataluña
(1990-91), and is currently associate physician for the Department of
Rehabilitation Therapy at the Germans Trias i Pujol University Hospital, where
she is responsible for the Rheumatological Rehabilitation Unit.
José María Salazar Vallinas, rheumatologist, Infanta
Cristina Hospital, Badajoz.
University graduate in Medicine and
Surgery (Autonomous University of Madrid,1977), specialist in Rheumatology via
the MIR (Ramón y Cajal Hospital, Madrid 1980-83), and in Family and Community
Medicine (Ministry of Education and Science, 1987). Master of Public Health
(National School of Health, Madrid, 1986). Formerly, President and Founding
Member of the Rheumatological Association of Extremadura and spokesperson for
the Spanish Society of Rheumatology, and responsible for residency training in
Family and Community Medicine and member of the Teaching Commission (1988-95)
and the Clinical Chart Commission (1990-1996) of the Infanta Cristina de Badajoz
University Regional Hospital. Also Associate Professor of the Health Sciences in
the Department of Human Clinical Pathology, Area of Medicine/Rheumatology, of
the University of Extremadura.
3. Investigators
The research team, originally from the UISS (most of whom currently work at TAISS), that was responsible for designing the study methodology, coordinating the work of the expert panel, carrying out the synthesis of the scientific evidence, and producing the final guideline document, was made up of the following persons:
Setefilla Luengo Matos (UISS). Design of the synthesis of
the evidence.
Doctor of Medicine (Autonomous University of Madrid,
1990) and specialist in Preventive Medicine and Public Health (La Paz Hospital,
1985). Master of Public Health (National School of Health). Area Chief at the
Agency for Health Technology Evaluation, Carlos III Health Institute,
Madrid.
José Manuel Estrada Lorenzo (TAISS). Bibliographic
search.
University graduate in Geography and History from the
Complutense University of Madrid (1986), specializing in documentation in the
Health Sciences.
Santiago Alonso Corral (UISS). Database
design.
University graduate in Medicine and Surgery (University of
Salamanca, 1987) and specialist in Preventive Medicine and Public Health (San
Carlos Clinical Hospital, Madrid, 2001). Master of Public Health (National
School of Health, 1997). Specialist in Health Information Systems (Complutense
University of Madrid, 1994) and Master in Applied Electronics (School of
Industrial Organisation, 1992).
Miguel Ángel Abad Hernández (FIdeM). Analysis of the
scientific evidence.
University graduate in Medicine (Complutense
University of Madrid, 1991) and specialist in Rheumatology via the MIR (Gregorio
Marañón University General Hospital of Madrid, 1997).
Hildegarda Godoy Tundidor (FIdeM). Analysis of the
scientific evidence.
University graduate in Medicine (Complutense
University of Madrid 1994) and specialist in Rheumatology via the MIR (Gregorio
Marañón University General Hospital of Madrid, 1998).
Sandra García Armesto (UISS). Analysis of the scientific
evidence.
University graduate in Medicine (Autonomous University of
Madrid) and Master of Public Health, specializing in Health Services Management
and Evaluation, from the University Center of Public Health (CUSP) in
Madrid.
Yesenia Tordecillas Echenique (FIdeM). Analysis of the
scientific evidence.
University graduate in Medicine (University of
Cartagena, Colombia, 1997). Has participated in various research projects in
Colombian hospitals. Trained in the methodology of scientific research and the
critical review of medical literature.
Yira Tordecillas Echenique (FIdeM). Analysis of the
scientific evidence.
University graduate in Medicine (University of
Cartagena, Colombia, 1996). Has participated in various research projects in
Colombian hospitals. Trained in the methodology of scientific research and the
critical review of medical literature.
Milena Gobbo Montoya (TAISS). General coordinator and editor
of GUIPCAR.
University graduate in Psychology (Autonomous University
of Madrid, 1984). Previous training and experience related with the practice of
clinical psychology and the administration and management of hospital
units.
This guideline is the fruit of collaboration among a number of institutions and persons, all of whom have helped to make it possible.
The SER, for its initiative in promoting the development of this guideline, monitoring activities, and providing the meeting ground for strategic discussions.
Novartis should receive special thanks, not only for its sensitivity in sponsoring the guideline, but also for not influencing its content or development except to ensure its timely completion. The investigators and panelists can thus confirm that their freedom of opinion and criteria was preserved so that this guideline is free of financing bias.
The ISCIII made a significant contribution to making this guideline possible, both by carrying out research activities in the UISS, and for generously allowing the use of its installations for various research meetings, including those of the panel.
TAISS, which assumed responsibility from the UISS for producing the guideline, contracted the UISS investigators to continue its development, and provided the site for various research meetings, including the last meeting of the panel.
FIdeM, for handling the contracting of non-UISS staff.
The panelists, who so generously dedicated their time, energy, and knowledge to producing this guideline, are responsible for developing the key parts of the guideline.
The investigators, who overcame difficult moments and maintained their enthusiasm throughout all phases of the project, from its initial design, to the synthesis of the evidence, and the final assemblage of the pieces that make up this guideline.
María Dolores Aguilar and Kathy Fitch, who provided suggestions in previous versions of the guideline, and Ignacio Lázaro, for his silent miracles in solving computer-related mysteries.
The librarians at the National Library of the Health Sciences and at the libraries of the 12 de Octubre and the Ramón y Cajal Hospitals, who helped locate the documents necessary for the synthesis of the evidence.
Rheumatoid arthritis (RA) affects some 200,000 persons in Spain, with 20,000 new cases emerging each year. RA reduces quality of life and functional capacity, produces work disability, and increases mortality. It has been estimated that the annual social cost of RA in Spain exceeds 200 billion pesetas (US$1.04 billion), of which 65 billion pesetas ($338.5 million) are devoted to health expenditures. There is evidence of large variability in the management of RA in Spain; this variability depends not only on patient or disease characteristics, but also on characteristics of the hospital, department, or physician providing patient care. These facts suggest that some diagnostic or therapeutic procedures are overused, while others may be underused.
For these reasons, in 1998 the Spanish Society of Rheumatology (SER) decided to develop a clinical practice guideline for the management of rheumatoid arthritis (GUIPCAR) to help physicians make decisions about the diagnosis and treatment of patients with RA. The objective of GUIPCAR is to develop standards of quality for the treatment of RA and to reduce the variability that does not depend on patient characteristics.
This guideline, aimed at rheumatologists, describes the diagnostic and management strategies for the evaluation and treatment of patients with RA. It focuses on RA in adults (excluding juvenile RA) and includes diagnosis, evaluation, prognosis, and treatments such as drugs, rehabilitation, and surgery. It does not cover other treatments such as acupuncture, and only briefly treats extra-articular complications of RA such as amyloidosis, anemia, or Sjögren’s syndrome.
The guideline begins with a description of its origin and justification in the preface and an explanation of its objectives. The methodology followed to develop the recommendations is then described. The recommendations for treatment with disease-modifying antirheumatic drugs (DMARDs) in this guideline are based on a synthesis of the best available scientific evidence, after making a systematic review of the clinical trials and meta-analyses that have been published. A total of 2,281 articles was identified, 103 of which met the inclusion criteria for this review. The rest of the recommendations or considerations are based on scientific evidence obtained without a systematic literature review, or on the opinions of the expert panel. The experts were chosen by the SER, applying a series of criteria designed to support their validity at the national level and to avoid conflicts of interest. The guideline describes how it can be used, its contents, and its limitations.
Chapter 1 focuses on the diagnosis of RA, chapter 2 on the initial evaluation, based on which, in chapter 3, patients are classified according to the number of swollen joints and the presence of erosions. The classification is further broken down by acute phase reactants, the health assessment questionnaire (HAQ), and rheumatoid factor (RF). The recommendations on medical treatment are presented in chapter 4, the criteria for response to treatment in chapter 5, and the adverse effects of medical treatment in chapter 6. Surgical, rehabilitative, and local treatments are covered in chapter 7. Chapter 8 describes the extra-articular complications of RA. The guideline includes an appendix with instruments to facilitate the clinician’s data collection for the initial classification and follow-up of patients with RA, and another appendix with the complete patient classification. To make it easier to follow the guideline recommendations, readers may wish to make use of a simplified algorithm or the other, complete algorithm. The key features of the guideline are contained in a summary version, the "quick reference guide."
The bibliography has been divided into two sections, one listing all the references provided by the panelists or the investigators without a systematic search, and the other listing all the references used in the systematic review.
The Health Services Research Unit (Unidad de Investigación en Servicios de Salud - UISS) of the Carlos III Health Institute was commissioned by the SER to develop GUIPCAR. The project took 2 years to complete. During this time, the UISS became a private entity under the name of Advanced Research Techniques in the Health Services (Técnicas Avanzadas de Investigación en Servicios de Salud -TAISS). Novartis financed this project. The investigators established the necessary mechanisms to ensure that the guidelines would have no financing bias and that the persons involved in its development would have no conflicts of interest.
In 1998 the Spanish Society of Rheumatology (SER) undertook the development of a Clinical Practice Guideline (CPG) to help physicians make decisions about the diagnosis and treatment of patients with rheumatoid arthritis (RA). This initiative of the SER was in response to a phenomenon frequently seen in clinical practice: the large variability in the use of diagnostic, therapeutic, and rehabilitative procedures. RA is a disease with a relatively high prevalence, affecting from 0.2 to 0.8% of the population in Spain. The different specialties and levels of care involved in its treatment are not always well coordinated. Furthermore, recent years have seen rapid innovation in medical treatment, with the appearance of new drugs, new forms of combined treatment, and numerous studies on the effects of the drugs utilized. The large amount of information produced as a result of the ever-growing growing number of studies, their variable methodological quality, and the complexity of comparing the results of different studies constitutes a major obstacle for clinicians in keeping up to date on important knowledge in their field. Thus came about the project to produce a CPG for the management of RA (GUIPCAR), which was undertaken by the Health Services Research Unit (UISS) of the Carlos III Health Institute. This project took 2 years to complete. During this time, the UISS became a private company with the name of Advanced Research Techniques in the Health Services (TAISS).
CPGs should be based on scientific evidence, but when such evidence is absent or contradictory, they may be complemented by unbiased techniques of handling expert opinion. This guideline uses both methods, and is based on three central tasks: 1) a synthesis of the evidence on the efficacy of disease-modifying antirheumatic drugs (DMARDs); 2) specific recommendations on the diagnosis, evaluation, and treatment of patients with RA made by a panel of experts, generally rheumatologists with scientific prestige proposed by the SER, following a methodology designed to produce CPG recommendations; and 3) assignment of the level of scientific evidence that supports each recommendation for treatment with DMARDs.
The ultimate objective of this guideline is to aid clinical decision making by offering recommendations for the therapeutic management of RA that are based on the best available evidence. We have tried to present the recommendations in a clear and agreeable manner, so that it is easy to find the information sought. We hope it will prove useful to those who face the difficult task of making decisions about different courses of treatment and that, in the final analysis, it will result in better outcomes for patients with RA.
RA is a systemic disease of unknown etiology, which is characterized by chronic inflammation of the diarthrodial joints. It is frequently associated with severe morbidity, functional abnormalities involving work disability, reduced quality of life, and increased mortality. RA affects all populations, with an estimated prevalence of about 0.8% and an incidence of approximately 0.5/1,000 population per year [Silman, 1993]. In Spain, RA affects about 5 of every 1,000 adults [Villaverde, 2000] and causes 5% of all permanent work disability [Tornero, 1998].
The economic impact of this disease is reflected in direct costs (physician visits, diagnostic tests, drugs, hospitalization) and indirect costs (loss of income due to work disability). In one health district of Madrid it has been estimated that the mean annual cost of a patient with RA is 1.11 million pesetas (about US $5,700) Some 70% of these costs are direct costs — 32% for patient care and 38% not for patient care — and 30% are indirect costs, that is, lost hours of work. If these results are extrapolated to the whole Spanish population, based on the estimated prevalence of RA in this country, the annual social costs of this disease would reach more than 200 billion pesetas ($1.04 billion), of which 65 billion ($338.5 million) would be for health costs.
As with most diseases, there is enormous variability in the management of RA — among countries, among institutions, among physicians, and even within the same physician — and in the use of diagnostic procedures, follow-up methods, and therapeutic and rehabilitative measures. At times it may be thought that health resources are used inappropriately, or that a variety of different recommendations are followed due to the large amount of information about the disease that appears in different publications or other channels of communication. Sometimes modifications in disease management are introduced even though they do not have a clear advantage over existing strategies, while at other times effective strategies may be ignored. Health professionals caring for RA patients are faced not only with a disease whose etiology, management, and diagnosis are complicated, but also with an enormous amount of information that is not always easy to interpret.
CPGs are one of the most appropriate instruments to decrease unnecessary variability and improve clinical practice. A CPG is defined as a set of "systematically defined statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances." A good CPG should have the attributes of validity, reliability, reproducibility, clinical applicability, flexibility, clarity, multidisciplinarity, and periodic review [IOM, 1990a; IOM, 1992]. CPGs are part of a cultural change which consists of moving from unsubstantiated confidence in the opinions of professionals to a more structured and well-founded support for clinical decisions.
The US Institute of Medicine (IOM) has suggested various criteria for selecting the contents of a CPG: first, the guideline should be applied to a clinical condition for which there is the potential to improve health for a significant number of persons; second, it should reduce clinically significant variations in services and procedures; third, it should reduce clinically significant variations in the outcomes of health care; and fourth, policies for guideline development should reflect the needs and priorities of the health system. Following these criteria, the SER considers that RA is a clinical condition that would benefit from the development of a CPG.
The objectives of this guideline are to improve the quality of care, to reduce variability in the management of RA, to move toward the integral management of RA, and to align clinical practice more closely with the best available scientific evidence.
Improving the Quality of Care
The quality of care can be seen, defined, and measured in many ways [Donabedian, 1980; OTA, 1988; Lohr, 1990; Rubenstein, 1990; Chassin, 1991; Brook, 1991; Keeler, 1992; Kassirer, 1993; Burstin, 1993; Gates, 1993; Miller, 1993; Hayward, 1993]. The IOM defines it as "the degree to which health services for individuals and populations increase the likelihood of desired health outcomes and are consistent with current professional knowledge" [IOM, 1990b]. According to the characteristics implicit in this definition, quality refers both to the physician-patient (individual) level and to the social (population) level; it can be measured in probabilistic terms (quantification of uncertainty); and it is based on scientific knowledge. Donabedian, who conceives quality of care as based on three dimensions (structure, process, and result), emphasizes the degree to which technology is used well in different centers or places [Donabedian, 1988].
Evaluating the quality of care is a critical component of the correct functioning of health systems. Quality of care can be evaluated and can dramatically improve medical practice [Brook, 1990]. It is rarely evaluated, however, even though sufficient methodological instruments are available.
Measuring outcomes is critically important in evaluating the quality of care. Two classic measures of the outcomes of clinical practice are efficacy and effectiveness. Efficacy refers to the patient outcome produced under ideal conditions (e.g., in a clinical trial), while effectiveness is the outcome produced under real conditions (e.g., in daily practice). The difference between efficacy and effectiveness can be produced by random error, by systematic error or bias (for example, the inventors of a drug or technology, consciously or subconsciously, may make it appear better than it really is), by variability in the quality of care, or by personal health characteristics that may or may not be controlled by the individual [Brook, 1990]. For this reason, the degree to which effectiveness (the effect achieved) approximates efficacy (the maximum achievable effect) can be considered as an indicator of the quality of care. This guideline will deal with both concepts.
Implementing quality measures involves constructive actions to establish a relation between the process of care and patient outcomes [Brook, 1990]. For example, statistically significant and clinically important differences have been shown in clinical outcomes depending on whether procedures are applied with a good or poor process of care [Kahn, 1990]. The evidence showing that improving the process of care leads to better outcomes and that CPGs are one of the instruments designed to improve the process of care is one of the reasons behind the development of this guideline.
Reducing Variability in the Management of Rheumatoid Arthritis
There is evidence that decisions made in identical clinical situations may differ depending on individual, institutional, or geographic factors that are unrelated with patient characteristics [IOM, 1990a; IOM, 1992]. This does not mean that variability in clinical practice is unacceptable. It may be acceptable when there is uncertainty about the advantages of one technique over another, when patient characteristics or preferences are different, when the characteristics of the center or its resources are different, or because of changing science or social and individual values. Such variability is not acceptable, however, when it is due to inadequate medical skill, poor institutional organization, ignorance, or the deliberate decision not to use procedures for which there is proven evidence of their superiority. Unacceptable clinical practice does not benefit patients; it may harm them, and it consumes resources unnecessarily.
In Spain there is large inter- and intra-hospital variability in the use of health resources, diagnostic procedures, and therapeutic procedures in patients with RA. For example, in one comparison among centers, the mean number of visits per person over a 2-year period ranged from a low of 5.1 (range 1-11) to a high of 10.2 (range 2-31). These differences remained after adjusting for disease severity and functional class, according to the preliminary results of the "Study of RA Management" (emAR). In the same study, the percentage of patients who underwent some orthopedic surgical procedure during the course of their disease ranged from 0 to 71%, depending on the center. Even though most patients were being treated with nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and DMARDs, the use of specific drugs varied significantly, independently of the patient’s clinical situation. That is, the variability observed cannot be explained solely by differences related with the disease itself, but is also associated with variables related with the hospital center, department, or physician responsible for the patient. This variability in RA management that cannot be explained by patient characteristics justifies the development of standards of quality for the treatment of RA.
Moving Toward Integral Management of Rheumatoid Arthritis
At any given time, a variety of specialists may collaborate in managing specific disease aspects, from diagnosis to treatment to follow-up. Primary care physicians, rheumatologists, radiologists, ophthalmologists, orthopedic surgeons, rehabilitation specialists, orthopedists, psychologists or psychiatrists, and even other, non-medical health personnel, should be aware of the need to unify criteria and to integrate care in accordance with the best available scientific evidence. One way to avoid RA patients’ receiving contradictory messages from different specialists is the development of CPGs that are easy to understand, and with a strong enough scientific basis to earn the support of all specialists who help manage patients with this disease.
Aligning Clinical Practice with the Best Available Scientific Evidence
Clinical practice in RA treatment has varied considerably in recent years, despite the fact that therapeutic resources have remained almost constant. There is growing use of early and aggressive treatment, which is supported by evidence that such measures may delay disease progression.
The controlled clinical trials showing the short-term efficacy of a treatment intervention in selected populations initially led to disparate treatment practices and options, which have not subsequently been supported by studies of effectiveness in persons with RA. For example, in clinical trials of short-term efficacy, the efficacy of all the available DMARDs is higher than that of placebo (PCB). In comparative studies of a similar duration, it is difficult to find evidence that one DMARD is better than others. In studies evaluating compliance with long-term treatment, the number of patients who continue taking a specific DMARD after 5 years is significantly higher for methotrexate. This type of evidence has led to the generalized use of methotrexate as the drug of choice in most centers that care for these patients.
There is insufficient scientific to support certain clinical decisions, however, and not all the scientific evidence is within easy reach of clinicians. Furthermore, the evidence available is of varying methodological quality, thus its scientific validity may be more or less solid. The use of more highly developed instruments to analyze information may facilitate changes in clinical practice as important as that of early intervention, based on the best available scientific evidence. Thus, this guideline is an attempt to base the process of care on the best available scientific evidence and, where this does not exist or is contradictory, applies the collective judgments of an expert panel selected according to specific criteria and using a scientific methodology developed to avoid biases.
The synthesis of the evidence in the development of CPGs has three objectives: 1) to base the recommendations on the best available scientific evidence; 2) to allow users to obtain the information on which the recommendations are based; and 3) to make it possible to evaluate the quality of the guideline.
One problem in carrying out a synthesis of the evidence is that the amount of information may be so extensive as to be impossible to cover. There are more than 35,000 medical journals in the world, which publish over 3 million articles every year. In addition, these journals are published in many different languages, the designs of the studies may be very heterogeneous, the methodological quality is highly variable, the patients selected may be very different, the measure of results may refer to different outcomes, and different subjects may be treated for the same intervention (e.g., whereas one study focuses on clinical outcomes, others may focus on complications, utilization, physiopathological mechanisms, or costs). This makes it necessary to limit the search for scientific evidence. Limiting such searches is justified not only by real limitations on resources and time, but also because a search aimed specifically at key aspects of disease management may constitute one of the strengths of a CPG. This naturally depends on achieving an intelligent balance among the topics searched, the quality of the review process, and the available resources. Thus, once the large number of RA publications had been explored, it was agreed that, for this guideline, the synthesis of the evidence would focus on the efficacy of DMARDs.
After making an initial estimate of the volume of literature to be reviewed, the project investigators and the members of the expert panel agreed to focus the synthesis of the evidence on studies evaluating the efficacy of treatment with DMARDs (clinical trials) by means of a systematic review. Table 1 shows the DMARDs included in the review.
The literature search for the synthesis of the evidence on the efficacy of
DMARDs in RA was made in four databases, for the time periods noted below:
The articles for the bibliographic search had to meet the following inclusion criteria: 1) controlled clinical trial, meta-analysis, or systematic review; 2) study referring to one or more of the selected DMARDs; 3a) comparison of the efficacy of a drug or combined therapy vs. another drug or combined therapy including at least one of the drugs listed in Table 1, or comparison of LEF or TNF with placebo; 3b) if a systematic review or meta-analysis, comparison of a drug or combined therapy vs. another drug or combined therapy including at least one of the drugs listed in table 1, or with placebo; 4) study carried out in patients with RA; 5) trial carried out in humans; and 6) published in English or Spanish.
The descriptors used were those specified in each database with regard to the research methodology (e.g., RANDOMIZED-CONTROLLED-TRIAL), rheumatoid arthritis (e.g., RHEUMATOID ARTHRITIS), and specific drugs (e.g., METHOTREXATE ).
We first identified all existing systematic reviews on DMARDs. Nine systematic reviews were located in the Cochrane Library that compared placebo with the following drugs: methotrexate, sulphasalazine, cyclosporin, oral gold salts, injectable gold salts, cyclophosphamide, d-penicillamine, azathioprine, and anti-malarials.
Using the search strategy described, we then located 982 bibliographic records in MEDLINE, 968 in EMBASE, 268 in the Cochrane Library, and 63 in IME, for a total of 2,281 records; of these, 666 were found in more than one database. Thus, the final number of records selected was 1,615.
All the bibliographic records selected were read independently by two reviewers (a rheumatologist and a physician with training in epidemiology), both of whom had received training in how to carry out a synthesis of the evidence. The objective of reading the title of the bibliographic record was to verify that the article met the inclusion criteria.
A 4-phase strategy was used to screen the records:
Of the 1,615 records selected, 289 were rejected during the first phase; thus, 1,326 bibliographic records went on to the second phase.
All the articles passing the first phase that did not have an abstract passed directly to the third stage.
Of the 1,326 articles that passed to the second phase, 1,225 had an abstract and 101 did not. After reading the abstract, 1,039 were eliminated and 186 were accepted and passed to the third phase, together with the 101 records with no abstract. That is, 287 articles passed to the "request for articles" stage.
In the first two stages of screening the records, each rheumatologist-methodologist team compared the records read and, in case of discrepancy, the two reviewers discussed the article. If no agreement was reached, the record was read by another pair of reviewers. Discrepancies between reviewers occurred in 4% of records, and agreement was reached in 100% of cases.
Objective 1: To identify the bibliographic information for each article included in the review. General information was obtained on the relevant bibliographic data of the article (e.g., first author, year of publication, journal). Each article was coded to facilitate its location in the database.
Objective 2: To verify that the article, in its complete
text, met the inclusion criteria for the review. This verification process
resulted in four possibilities:
Redundant or complementary articles were identified a posteriori after reading the articles, by verifying that the study was written by the same authors, used the same guidelines for the treatments compared, and used the same study design.
Objective 3: To collect the relevant clinical information from each article accepted. If the article met the inclusion criteria, data were collected on the number and characteristics of the participants (gender, age, mean time of disease progression, previous use of NSAIDs and DMARDs), interventions, outcome measures evaluated, persons lost to follow-up and withdrawals from the study, reliability of the measurement instruments used, follow-up of the groups, and statistical analysis.
Objective 4: To assess the methodological quality and level of evidence of the trials. The methodological quality of the trials was assessed using the Jadad scale for rating the quality of clinical trials (Table 2) [Jadad, 1996a]. The level of evidence was assessed in accordance with the Hadorn scale designed to evaluate the quality of the evidence of publications used to develop CPGs (Table 3) [Hadorn, 1996].
To rate the quality of a clinical trial, three questions are posed:
One point is given for each "yes" and 0 points for each "no". There are no intermediate scores.
An additional point is given in question 1 if the randomization method is described and is appropriate, and an additional point is given in question 2 if the method for making the study double blind is described and is appropriate.
One point is subtracted in question 1 if the randomization method is described but is inappropriate, and one point is subtracted in question 2 if the study is described as double blind, but the blinding method is inappropriate.
An article can receive a score of 0 to 5 points. An article is considered to be of good quality if the score is 3 or higher, and of poor quality if the score is less than 3.
Level of evidence | |
---|---|
1. Well-conducted multicenter randomized controlled trials including
100 or more patients |
A |
2. Well-conducted randomized controlled trials with fewer than 100
patients, in one or more institutions | |
3. Well-conducted cohort studies | |
4. Well-conducted case-control studies | B |
5. Poorly controlled or uncontrolled studies | |
6. Conflicting evidence in favor of the recommendation | |
7. Expert opinion | C |
Levels 1, 2, and 3 refer to a high level of evidence (A); levels 4, 5, and 6 refer to a level of evidence with potential biases that could invalidate the results (B); and level 7 is the evidence most vulnerable to potential biases (C).
Since only clinical trials were evaluated in the synthesis of the evidence for this guideline, the levels of evidence assigned are A1 (1 on the Hadorn scale ), A2 (2 on the Hadorn scale), and B (5 on the Hadorn scale).
Data collection form. A form was designed to collect the bibliographic data for each article, information about the study methodology, clinical data, the quality of the methodology, and the level of evidence. The first version of the form was evaluated by three reviewers (two rheumatologists and one methodologist) who applied it to 10 articles. After introducing the appropriate modifications, the reviewers began to use the form. It was necessary to change the form for later articles, however, in order to adapt it to the peculiarities of each trial (for example, the number of interventions compared, outcomes measured, and so on) and to be able to create homogeneous and unbiased evidence tables. After 13 successive versions, the definitive form was obtained, which was sufficiently valid to permit inclusion and categorization of the relevant information from each article. This form is available to interested readers (milena@taiss.com).
Evaluation of the articles. Five reviewers read and evaluated the articles: two specialists in rheumatology and three in research methodology. All had been trained in techniques for the critical review of the scientific literature. Each article was read independently by two reviewers, one physician with training in epidemiology and one rheumatologist. Each reviewer completed one form for each article. Each epidemiologist-rheumatologist team then compared the individual forms and, if they agreed, completed the final form. The two reviewers discussed any discrepancies in an attempt to reach consensus. If they did not agree, the article was read and discussed by all the reviewers until agreement was reached, at which point the final form was completed.
Each form made up one record in the database designed for the synthesis of the evidence. The form describes a comparison between two different treatment interventions. This means that a trial assessing more than two treatment interventions, making different comparisons among them, would give rise to more than one form. Thus, the number of forms is larger than the number of clinical trials included in the synthesis of the evidence.
Of the 287 articles requested, 162 did not meet at least one of the inclusion criteria, 13 were redundant and 9 were articles comparing drugs with placebo that had already been included in the systematic reviews of the Cochrane Library. Consequently, a total of 103 articles was included in the review, 91 of which were different clinical trials (12 were complementary articles), allowing 140 comparisons between different treatment strategies (single drugs or combinations thereof). Thus, there are 140 records in the database for the efficacy of DMARDs (see Table 4).
(Table 4 of the GUIPCAR CLINICAL PRACTICE GUIDELINE FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS guideline is available in the original guideline document.)
These 91 trials and the 140 resulting comparisons are grouped by the Jadad and Hadorn scales for classifying the quality of the evidence as shown in Tables 5 and 6, respectively.
LEVEL OF EVIDENCE (Jadad Scale) |
CLINICAL TRIALS | COMPARISONS |
---|---|---|
1 | 7 (8%) | 7 (5%) |
2 | 19 (21%) | 24 (17%) |
3 | 18 (20%) | 31 (22%) |
4 | 32 (35%) | 53 (38%) |
5 | 15 (16%) | 25 (18%) |
TOTAL | 91 (100%) | 140 (100%) |
LEVEL OF EVIDENCE (Hadorn Scale) |
CLINICAL TRIALS | COMPARISONS |
---|---|---|
A1 | 13 (14%) | 25 (18%) |
A2 | 13 (14%) | 20 (14%) |
B | 65 (72%) | 95 (68%) |
TOTAL | 91 (100%) | 140 (100%) |
Thirty-eight of the 140 comparisons assessed a DMARD vs. certain drugs not included in the systematic review (e.g., collagen II, tiopronin, or pyrithinol). These 38 comparisons were excluded because the expert panel believed they were not relevant. Thus, the final 102 comparisons refer only to the DMARDs listed in Table 1.
For the purposes of the synthesis of the evidence, the comparisons were grouped by drug to make it easier to find the clinical trials comparing a specific drug (alone or in combination) with any of the other drugs in table 1 (also alone or in combination).
For each possible comparison we identified the number of existing studies, their level of evidence, and the intervention favored by the outcome measures collected in each study. (The tables synthesizing the outcome measures collected in each study for the comparisons are available to interested readers by contacting milena@taiss.com).
The panel was consulted when a) different studies comparing the same drugs included different outcome measures, some (e.g., clinical effect) in favor of one treatment intervention and others (e.g., radiographic results) in favor of the other intervention; and b) to assess the clinical relevance of some outcome measures with statistically significant differences when the differences were not significant for many other outcomes. In these divergent cases, greater weight was given to outcome measures in agreement with the American College of Rheumatology (ACR) criteria, especially the number of swollen joints and radiographic damage. For example, a study with A2 level evidence comparing chloroquine with oral gold salts shows significant differences in favor of chloroquine with regard to strength of grip and morning stiffness; however, functional status is significantly better in the group with oral salts, and no significant differences are found between the two groups with regard to the number of swollen joints, pain, or acute phase reactants. In this case it was concluded that there were no important clinical differences in the efficacy of chloroquine and oral gold salts.
Evidence tables
The results of the synthesis of the evidence are shown in Tables 7 and 8. Table 7 includes the comparisons of DMARDs used in monotherapy. Table 8 includes the comparisons of single or combined drugs vs. combinations of drugs.
For those comparisons for which evidence exists, there are three lines in the corresponding box with the following data:
Line 1. | Number of studies and level of evidence of these studies (e.g., "3-A1; 2-B" means there are three studies with an A1 level of evidence and two with level B). |
Line 2. |
The identification numbers for these articles (used as the
bibliographic reference). Numbers separated by a dash (e.g., 7-9) mean that all articles in the interval are included (7, 8, and 9). Numbers separated by a comma (e.g., 7, 9) represent references only to those specific articles (7 and 9). |
Line 3. |
One of the following possibilities is shown in bold print: - The drug or combination of drugs (COMB) which the evidence favors (using the abbreviations shown in table 1.) - NS: if the differences are not significant. |
PCB | AUR | AZA | CPA | CLQ | CSA | DP | ETN | HCQ | IFM | LEF | MTX | IG | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
CPA |
1-B 1 CPA |
||||||||||||
CLQ |
1-A2 2 NS |
1-B 3 NS |
|||||||||||
CSA |
1-B 4 NS |
1-A2 5 NS |
|||||||||||
DP |
1-B 6 DP |
3-B 7-9 NS |
1-B 10 NS |
1-A2 11 NS |
|||||||||
ETN |
2A1;1B 12-14 ETN |
2-A1 15,72 NS |
|||||||||||
HCQ |
1-B 16 NS |
2-B 17-18 NS |
|||||||||||
IFM |
2-A2 19,20 IFM |
1-A2 21 DOSE=10* |
|||||||||||
LEF |
2-A1;3-B 22-26 LEF |
||||||||||||
MTX |
1-A1;1-B 27, 28 MTX |
2-A2;2-B 29-32 MTX |
1-B 33 NS |
2-A1 72 NS |
3-B 34-36 NS |
1-A1;2-B 37-39 NS |
|||||||
IG |
1-A1;1-A2; 8-B 40-49 NS |
2-B 50,51 AZA |
1-B 52 CPA |
1-B 53 NS |
1-A2 54 NS |
3-B 55-57 NS |
1-A2;4-B 58-62 NS |
||||||
SSZ |
1-B 63 NS |
2-B 64, 65 NS |
2-A2 66, 67 SSZ |
1-A1 68 NS |
1-A1;1-A2 69, 70 NS |
1-B 71 NS |
* Compares doses of 1 mg/kg vs. 10 mg/kg
AUR+MTX | AZA+MTX | CLQ+DP | MTX+CLQ | CSA+IG | CSA+MTX | HCQ+DP | MTX+ETN | HCQ+IG | SSZ+HCQ | HCQ+MTX | MTX+SSZ+HCQ | IFM+MTX | MTX+SSZ | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AUR |
1-B 73 NS |
|||||||||||||
AZA |
1-B 74 COMB |
|||||||||||||
CPA |
||||||||||||||
CLQ |
1-B 75 NS |
|||||||||||||
CSA |
||||||||||||||
DP |
1-B 76 NS |
1-B 77 NS |
||||||||||||
ETN |
||||||||||||||
HCQ |
1-B 78 NS |
1-A2 79 COMB |
1-B 80 COMB |
|||||||||||
IFM |
||||||||||||||
LEF |
||||||||||||||
MTX |
1-B 81 NS |
1-B 82 COMB |
1-A2 83 COMB |
1-A1 84 COMB |
1-B 85 COMB |
1-A2 86 COMB |
7-B 87-93 COMB |
1-A1:1-A2 94,95 NS | ||||||
IG |
1-B 96 NS |
1-A1;1-B 97,98 NS |
||||||||||||
SSZ |
1-A2 99 NS |
1-A1:1-A2 100, 101 NS | ||||||||||||
SSZ+HCQ |
1-A2 102 COMB. TRIP. |
Tables 9a and 9b show the mean time of disease progression, previous use of DMARDs (if the box is blank, this data was not included in the article), duration of treatment in the trial (if the box is blank, this data was not included in the article), the level of evidence, the bibliographic reference for each comparison (cited in references 2.2, 2.3, and 2.4), and the identification number for each article (used to locate it in Tables 7 and 8).
DMARDs compared (used in monotherapy) |
Mean time of RA progression (in months) |
Previous DMARD use |
Duration of treatment (in weeks) |
Level of evidence |
Bibliographic reference |
ID N° | |
---|---|---|---|---|---|---|---|
Azathioprine | Cyclophosphamide | 60 | 72 | B | 1, R1 | 1 | |
Oral gold salts | Chloroquine | 39.4 | 24 | A2 | 2 | 2 | |
Azathioprine | Chloroquine | 23 | 24 | B | 3 | 3 | |
Cyclosporin | Azathioprine | 79.2 | YES | 26 | B | 4 | 4 |
Cyclosporin | Chloroquine | 78 | NO | 24 | A2 | 5 | 5 |
Oral gold salts | D-penicillamine | 83 | YES | 52 | B | 6 | 6 |
Azathioprine | D-penicillamine | 113.4 | 52 | B | 7, R2 | 7 | |
134 | YES | 24 | B | 8 | 8 | ||
132 | YES | 96 | B | 9 | 9 | ||
D-penicillamine | Chloroquine | 30 | YES | 48 | B | 10 | 10 |
Cyclosporin | D-penicillamine | 86.4 | YES | 24 | A2 | 11 | 11 |
Etanercept | Placebo | 150 | YES | 26 | A1 | 12 | 12 |
138 | YES | 26 | A1 | 12 | 13 | ||
YES | 12 | B | 13 | 14 | |||
Etanercept | Etanercept | 144 | YES | 26 | A1 | 12 | 15 |
Oral gold salts | Hydroxychloroquine | 124.5 | 48 | B | 14 | 16 | |
Hydroxychloroquine | D-penicillamine | 71.4 | YES | 96 | B | 15 | 17 |
NO | 96 | B | 16 | 18 | |||
Infliximab | Placebo | 99 | YES | 4 | A2 | 17 | 19 |
97.8 | YES | 4 | A2 | 17 | 20 | ||
Infliximab | Infliximab | 88.8 | YES | 4 | A2 | 17 | 21 |
Leflunomide | Placebo | 79.8 | YES | 24 | A1 | 18 | 22 |
83.4 | YES | 52 | A1 | 19, R3 | 23 | ||
96 | YES | 24 | B | 20 | 24 | ||
100.8 | YES | 24 | B | 20 | 25 | ||
102.6 | YES | 24 | B | 20 | 26 | ||
Methotrexate | Oral gold salts | 70.3 | YES | 36 | A1 | 21, C1 | 27 |
59.5 | NO | 48 | B | 22, C2 | 28 | ||
Methotrexate | Azathioprine | 104.4 | YES | 24 | A2 | 23 | 29 |
133.2 | YES | 24 | A2 | 24, R4, R5 | 30 | ||
96 | YES | 48 | B | 25, R6, R7 | 31 | ||
156 | YES | 24 | B | 26 | 32 | ||
Cyclosporin | Methotrexate | 25.8 | NO | 96 | B | 27 | 33 |
Infliximab | Methotrexate | 91.2 | YES | 26 | B | 28 | 34 |
92.4 | YES | 26 | B | 28 | 35 | ||
103.8 | YES | 26 | B | 28 | 36 | ||
Leflunomide | Methotrexate | 81 | YES | 52 | A1 | 19 | 37 |
45 | YES | 52 | B | 29 | 38 | ||
43.8 | YES | 104 | B | 29 | 39 | ||
Oral gold salts | Injectable gold | 76 | 21 | A1 | 30, C3, R8, R9 | 40 | |
115.8 | YES | 96 | B | 31 | 41 | ||
83.4 | 48 | B | 32 | 42 | |||
61.8 | YES | 96 | B | 33, C4 | 43 | ||
144 | YES | 48 | A2 | 34 | 44 | ||
63.6 | NO | 48 | B | 35 | 45 | ||
109.2 | NO | 24 | B | 36 | 46 | ||
45.6 | YES | 52 | B | 37, C5 | 47 | ||
63 | 48 | B | 38 | 48 | |||
24 | 48 | B | 39, C6, R10 | 49 | |||
Azathioprine | Injectable gold | 60 | 72 | B | 1 | 50 | |
25 | 24 | B | 3 | 51 | |||
Cyclophosphamide | Injectable gold | 48 | 72 | B | 1 | 52 | |
Injectable gold | Chloroquine | 20 | 24 | B | 3 | 53 | |
Cyclosporin | Injectable gold | 11.76 | YES | 72 | B | 40 | 54 |
Injectable gold | D-penicillamine | 66 | 24 | B | 41, R11 | 55 | |
14.8 | 48 | B | 42 | 56 | |||
21 | B | 43 | 57 | ||||
Injectable gold | Methotrexate | NO | 26 | B | 44 | 58 | |
14 | 48 | B | 45 | 59 | |||
17.5 | YES | 24 | B | 46 | 60 | ||
23.9 | YES | 144 | B | 47, C7, C8 | 61 | ||
68.4 | YES | 26 | A2 | 48 | 62 | ||
Sulphasalazine | Oral gold salts | 114 | YES | 240 | B | 49, C9 | 63 |
Sulphasalazine | D-penicillamine | 84 | 576 | B | 50, C10 | 64 | |
105 | 48 | B | 51 | 65 | |||
Hydroxychloroquine | Sulphasalazine | 12.8 | NO | 48 | A2 | 52, C11, C12, R12 | 66 |
75.6 | YES | 24 | A2 | 53 | 67 | ||
Leflunomide | Sulphasalazine | 90 | YES | 24 | A1 | 18 | 68 |
Sulphasalazine | Methotrexate | 3.05 | NO | 52 | A2 | 54 | 69 |
14.6 | NO | 52 | A1 | 55 | 70 | ||
Injectable gold | Sulphasalazine | 68 | NO | 48 | B | 56 | 71 |
Etanercept | Methotrexate | 11.5 | YES | 48 | A1 | 57 | 72 |
DMARDs compared (used in monotherapy or combined therapy vs. drug combinations) |
Mean time of RA progression (in months) |
Previous DMARD use |
Duration of treatment (in weeks) |
Level of evidence |
Bibliographic reference |
ID N° | |
---|---|---|---|---|---|---|---|
Oral gold salts | Methotrexate Oral gold salts |
64.5 | NO | 48 | B | 22 | 73 |
Azathioprine | Methotrexate Azathioprine |
96 | YES | 48 | B | 25, R6, R7 | 74 |
Chloroquine | Chloroquine D-penicillamine |
24 | YES | 48 | B | 10 | 75 |
D-penicillamine | Chloroquine D-penicillamine |
18 | YES | 48 | B | 10 | 76 |
D-penicillamine | Hydroxychloroquine D-penicillamine |
72.6 | YES | 96 | B | 15 | 77 |
Hydroxychloroquine | Hydroxychloroquine D-penicillamine |
70.8 | YES | 96 | B | 15 | 78 |
Hydroxychloroquine | Sulphasalazine Hydroxychloroquine |
75.6 | YES | 24 | A2 | 53 | 79 |
Hydroxychloroquine | Hydroxychloroquine Methotrexate |
24 | B | 58 | 80 | ||
Methotrexate | Methotrexate Oral gold salts |
69 | NO | 48 | B | 22 | 81 |
Methotrexate | Methotrexate Azathioprine |
96 | YES | 48 | B | 25 | 82 |
Methotrexate | Methotrexate Chloroquine |
92.58 | 24 | A2 | 59 | 83 | |
Methotrexate | Methotrexate Cyclosporin |
122.4 | YES | 24 | A1 | 60 | 84 |
Methotrexate | Methotrexate Etanercept |
156 | YES | 24 | B | 61 | 85 |
Methotrexate | Methotrexate Sulphasalazine Hydroxychloroquine |
120 | YES | 96 | A2 | 62 | 86 |
Methotrexate | Infliximab Methotrexate |
103.8 | YES | 54 | B | 63, R13 | 87 |
96.6 | YES | 54 | B | 63, R13 | 88 | ||
107.4 | YES | 54 | B | 63, R13 | 89 | ||
105.6 | YES | 54 | B | 63, R13 | 90 | ||
131.4 | YES | 26 | B | 28 | 91 | ||
118.2 | YES | 26 | B | 28 | 92 | ||
112.2 | YES | 26 | B | 28 | 93 | ||
Methotrexate | Methotrexate Sulphasalazine |
14.5 | NO | 52 | A1 | 55 | 94 |
2.8 | NO | 52 | A2 | 54 | 95 | ||
Injectable gold | Injectable gold Cyclosporin |
133.2 | YES | 24 | A2 | 64 | 96 |
Injectable gold | Hydroxychloroquine Injectable gold |
24 | YES | 48 | A1 | 65 | 97 |
78 | YES | 24 | B | 66 | 98 | ||
Sulphasalazine | Sulphasalazine Hydroxychloroquine |
75.6 | YES | 24 | A2 | 53 | 99 |
Sulphasalazine | Methotrexate Sulphasalazine |
10.7 | NO | 52 | A1 | 55 | 100 |
2.9 | NO | 52 | A2 | 54 | 101 | ||
Sulphasalazine Hydroxychloroquine |
Methotrexate Sulphasalazine Hydroxychloroquine |
96 | YES | 96 | A2 | 62 | 102 |
Evaluation of the methodological quality of meta-analyses
The quality of the Cochrane Library meta-analyses was rated using the index of the quality of review articles, as revised by Oxman and Guyatt [Oxman, 1991a; Oxman, 1991b; Jadad, 1996b].
This index is based on answers to the following questions:
No | Partially | Yes |
ACR (66/68) |
Ritchie (53) |
NSJ (44) |
Fuchs (28) | |
Cervical spine | - | +*m | - | - |
Temporomandibular | + | +* | - | - |
Sternoclavicular | + | +* | + | - |
Acromioclavicular | + | +* | + | - |
Shoulder | + | + | + | + |
Elbow | + | + | + | + |
Wrist | + | + | + | + |
Metacarpophalangeal | + | +* | + | + |
Proximal interphalangeal | + | +* | + | + |
Distal interphalangeal | + | - | - | - |
Hip | + | +m | - | - |
Knee | + | + | + | + |
Ankle | + | + | + | - |
Subtalar | + | +m | - | - |
Midtarsal | + | +*m | - | - |
Metatarsophalangeal | + | +* | + | - |
Interphalangeal (foot) | + | - | - | - |
- The joints marked with an asterisk (*) are counted as a
single joint. - In the ARA/ACR index the subtalar and midtarsal joints are counted as a single joint. - The Ritchie index counts (0-3) the presence of tenderness or pain on motion (m) |
Disease Activity Score
Ranges from 0 (no disease activity) to 10 (maximum disease activity)
DAS28 with four variables:
DAS28=0.56(√NPJ28)+0.28(√NSJ28)+0.70(In ESR)+0.014(PGA)
DAS28 with three variables:
DAS28=0.56 (√NPJ28) + 0.28 (√NSJ28) + 0.70 (In ESR) + 1.08 + 0.16
Formula to transform original DAS to DAS28:
DAS28 = 1.072 (DAS) + 0.938
Original DAS with four variables:
DAS=0.54(√RI) +0.065(NSJ44) + 0.33(In ESR) + 0.0072(PGA)
Original DAS with three variables:
DAS = 0.54 (√RI) + 0.065 (NSJ44) + 0.33 (In ESR) + 0.224
NPJ28: Number of painful joints based on a count of 28 joints
NSJ28:
Number of swollen joints based on a count of 28 joints
ln: Natural
logarithm
ESR: Erythrocyte sedimentation rate
PGA: Patient’s global
assessment of health or disease on a VAS from 0 (very good) to 100
(very
poor). Either of the two scales produces the same results, although the latter
one is
preferable.
RI: Ritchie index
NSJ44: Number of swollen joints
based on a count of 44 joints
The following list shows how the 144 different patient scenarios were classified as a function of disease characteristics, together with the recommended treatment/s in each case.
A.1. No erosions and has NOT taken NSAIDs and/or corticosteroids during the last 3 months | |||
1. Normal acute phase reactants | |||
a. | HAQ <1 | ||
- RF <40 | NSAIDs and/or corticosteroids | ||
- RF 40-100 | NSAIDs and/or corticosteroids or chloroquine | ||
- RF >100 | NSAIDs and/or corticosteroids or chloroquine or sulphasalazine | ||
b. | HAQ ≥1 | ||
- RF <40 | NSAIDs and/or corticosteroids | ||
- RF 40-100 | NSAIDs and/or corticosteroids or chloroquine or sulphasalazine | ||
- RF >100 | NSAIDs and/or corticosteroids or chloroquine or sulphasalazine | ||
2. Elevated acute phase reactants | |||
a. | HAQ <1 | ||
- RF <40 | NSAIDs and/or corticosteroids or chloroquine or sulphasalazine | ||
- RF 40-100 | NSAIDs and/or corticosteroids or chloroquine or sulphasalazine | ||
- RF >100 | NSAIDs and/or corticosteroids or methotrexate | ||
b. | HAQ ≥1 | ||
- RF <40 | NSAIDs and/or corticosteroids or methotrexate or chloroquine | ||
- RF 40-100 | NSAIDs and/or corticosteroids or methotrexate | ||
- RF >100 | NSAIDs and/or corticosteroids or methotrexate |
A.2. No erosions and HAS taken NSAIDs and/or corticosteroids during the last 3 months | |||
1. Normal acute phase reactants | |||
a. | HAQ <1 | ||
- RF <40 | Chloroquine | ||
- RF 40-100 | Chloroquine or methotrexate | ||
- RF >100 | Chloroquine or methotrexate | ||
b. | HAQ ≥1 | ||
- RF <40 | Methotrexate or sulphasalazine or chloroquine | ||
- RF 40-100 | Methotrexate or sulphasalazine | ||
- RF >100 | Methotrexate or sulphasalazine | ||
2. Elevated acute phase reactants | |||
a. | HAQ <1 | ||
- RF <40 | Chloroquine or sulphasalazine or methotrexate | ||
- RF 40-100 | Methotrexate or sulphasalazine | ||
- RF >100 | Methotrexate | ||
b. | HAQ ≥1 | ||
- RF <40 | Methotrexate or sulphasalazine | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate |
B. From 1 to 3 erosions | |||
1. Normal acute phase reactants | |||
a. | HAQ <1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate | ||
b. | HAQ ≥1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate | ||
2. Elevated acute phase reactants | |||
a. | HAQ <1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate | ||
b. | HAQ ≥1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate |
C. More than 3 erosions | |||
1. Normal acute phase reactants | |||
a. | HAQ <1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate | ||
b. | HAQ ≥1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate | ||
2. Elevated acute phase reactants | |||
a. | HAQ <1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate | ||
b. | HAQ ≥1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate |
A.1. No erosions and has NOT taken NSAIDs and/or corticosteroids during the last 3 months | |||
1. Normal acute phase reactants | |||
a. | HAQ <1 | ||
- RF <40 | NSAIDs and/or corticosteroids or methotrexate | ||
- RF 40-100 | NSAIDs and/or corticosteroids or methotrexate | ||
- RF >100 | NSAIDs and/or corticosteroids or methotrexate or injectable gold | ||
b. | HAQ ≥1 | ||
- RF <40 | NSAIDs and/or corticosteroids or methotrexate | ||
- RF 40-100 | NSAIDs and/or corticosteroids or methotrexate | ||
- RF >100 | NSAIDs and/or corticosteroids or methotrexate or injectable gold | ||
2. Elevated acute phase reactants | |||
a. | HAQ <1 | ||
- RF <40 | NSAIDs and/or corticosteroids or methotrexate | ||
- RF 40-100 | NSAIDs and/or corticosteroids or methotrexate or injectable gold | ||
- RF >100 | Methotrexate | ||
b. | HAQ ≥1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate |
A.2. No erosions and HAS taken NSAIDs and/or corticosteroids during the last 3 months | |||
1. Normal acute phase reactants | |||
a. | HAQ <1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate or injectable gold | ||
b. | HAQ ≥1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate or injectable gold | ||
- RF >100 | Methotrexate or injectable gold | ||
2. Elevated acute phase reactants | |||
a. | HAQ <1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate | ||
b. | HAQ ≥1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate |
B. From 1 to 3 erosions | |||
1. Normal acute phase reactants | |||
a. | HAQ <1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate | ||
b. | HAQ ≥1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate | ||
2. Elevated acute phase reactants | |||
a. | HAQ <1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate | ||
b. | HAQ ≥1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate |
C. More than 3 erosions | |||
1. Normal acute phase reactants | |||
a. | HAQ <1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate | ||
b. | HAQ ≥1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate | ||
2. Elevated acute phase reactants | |||
a. | HAQ <1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate | ||
b. | HAQ ≥1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate |
A.1 No erosions and has NOT taken NSAIDs and/or corticosteroids during the last 3 months | |||
1. Normal acute phase reactants | |||
a. | HAQ <1 | ||
- RF <40 | NSAIDs and/or corticosteroids or methotrexate or injectable gold | ||
- RF 40-100 | NSAIDs and/or corticosteroids or methotrexate or injectable gold | ||
- RF >100 | NSAIDs and/or corticosteroids or methotrexate or injectable gold | ||
b. | HAQ ≥1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate | ||
2. Elevated acute phase reactants | |||
a. | HAQ <1 | ||
- RF <40 | NSAIDs and/or corticosteroids or methotrexate or injectable gold | ||
- RF 40-100 | NSAIDs and/or corticosteroids or methotrexate or injectable gold | ||
- RF >100 | NSAIDs and/or corticosteroids or methotrexate or injectable gold | ||
b. | HAQ ≥1 | ||
- RF <40 | NSAIDs and/or corticosteroids or methotrexate or injectable gold | ||
- RF 40-100 | Methotrexate or injectable gold | ||
- RF >100 | Methotrexate or injectable gold |
A.2 No erosions and HAS taken NSAIDs and/or corticosteroids during the last 3 months | |||
1. Normal acute phase reactants | |||
a. | HAQ <1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate | ||
b. | HAQ ≥1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate | ||
2. Elevated acute phase reactants | |||
a. | HAQ <1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate | ||
b. | HAQ ≥1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate |
B. From 1 to 3 erosions | |||
1. Normal acute phase reactants | |||
a. | HAQ <1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate or injectable gold | ||
b. | HAQ ≥1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate or methotrexate + injectable gold | ||
- RF >100 | Methotrexate or methotrexate + injectable gold | ||
2. Elevated acute phase reactants | |||
a. | HAQ <1 | ||
- RF <40 | Methotrexate or leflunomide | ||
- RF 40-100 | Methotrexate or leflunomide | ||
- RF >100 | Methotrexate or leflunomide | ||
b. | HAQ ≥1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate or methotrexate + injectable gold | ||
- RF >100 | Methotrexate or methotrexate + injectable gold |
C. More than 3 erosions | |||
1. Normal acute phase reactants | |||
a. | HAQ <1 | ||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate | ||
- RF >100 | Methotrexate or injectable gold or leflunomide | ||
b. HAQ ≥1 | |||
- RF <40 | Methotrexate | ||
- RF 40-100 | Methotrexate or methotrexate + injectable gold | ||
- RF >100 | Methotrexate or methotrexate + injectable gold | ||
2. Elevated acute phase reactants | |||
a. | HAQ <1 | ||
- RF <40 | Methotrexate or methotrexate + sulphasalazine | ||
- RF 40-100 | Methotrexate or leflunomide | ||
- RF >100 | Methotrexate or leflunomide | ||
b. HAQ ≥1 | |||
- RF <40 | Methotrexate or injectable gold | ||
- RF 40-100 | Methotrexate or methotrexate + injectable gold | ||
- RF >100 | Methotrexate or methotrexate + injectable gold |
Table 1. | Disease modifying antirheumatic drugs included in the systematic literature review |
Table 2. | Jadad scale for rating the quality of evidence from clinical trials |
Table 3. | Hadorn scale for rating the quality of scientific evidence from articles for CPGs |
Table 4. | Outline of article selection process |
Table 5. | Clinical trials and comparisons by the Jadad scale for rating the quality of the evidence |
Table 6. | Clinical trials and comparisons by the Hadorn scale for rating the quality of the evidence |
Table 7. | Comparisons of DMARDs used only in monotherapy |
Table 8. | Comparisons of single or combined DMARDs vs. drug combinations |
Table
9a. |
Mean time of RA progression, previous DMARD use, duration of treatment
in the trial, level of evidence, bibliographic reference, and ID number in the comparisons of DMARDs used in monotherapy included in the synthesis of the evidence |
Table
9b. |
Mean time of RA progression, previous DMARD use, duration of treatment
in the trial, level of evidence, bibliographic reference, and ID number in the comparisons of DMARDs used in monotherapy or combined therapy vs. drug combinations included in the synthesis of the evidence |
Table 10. | Evaluation of the quality of the meta-analyses of DMARDs |
Table 11. | Conclusions of the Cochrane Library meta-analyses and their level of evidence |
Table 12. | Predictive values (%) for RA diagnostic criteria in different settings |
Table 13. | Summary of instruments for the measurement of parameters in RA evaluation |
Table 14. | Initial treatment by simplified clinical classification of RA |
Table 15. | Alternative treatment in case of severe toxicity to initial treatment |
Table 16. | Alternative treatment in case of unsatisfactory response to initial treatment |
Table 17. | Recommended doses and commercial names of DMARDs |
Table 18. | Usual dosage and frequency of administration of NSAIDs |
Table 19. | Classification of the corticosteroids by duration of action |
Table 20. | Use of DMARDs during pregnancy and breast-feeding |
Table 21. | EULAR definition of response |
Table 22. | CPA dosage producing toxicity |
Table 23. | Percentage of women treated with CPA who develop amenorrhea |
Table 24. | Adverse effects of DMARDs |
Table 25. | Definition and characteristics of anemia in RA |
Table 26. | RA-independent risk factors for osteoporosis |
Table 27. | RA-associated risk factors for osteoporosis |
Abu-Shakra, 1994
Abu Shakra M, Nicol P, Urowitz MB.
Accelerated nodulosis, pleural effusion, and pericardial tamponade during
methotrexate therapy. J Rheumatol 1994; 21(5): 934-7.
ACR Committee, 1996
American College of Rheumatology Ad
Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in
rheumatoid arthritis. Arthritis Rheum 1996; 39(5): 723-31.
Ahmed, 1984
Ahmed AR, Hombal SM. Cyclophosphamide
(Cytoxan): a review on relevant pharmacology and clinical uses. J Am Acad
Dermatol 1984; 11(6): 1115-26.
Alarcón, 1987
Alarcon GS, Blackburn WD Jr, Calvo A,
Castaneda O. Evaluation of the American Rheumatism Association preliminary
criteria for remission in rheumatoid arthritis: a prospective study. J Rheumatol
1987; 14(1): 93-6.
Alarcón, 1994
Alarcón GS, Macaluso M, Singh K, et al.
Excess mortality in MTX-treated RA patients is not due to cancer or
cardiovascular diseases. Arthritis Rheum 1994; 37: S421.
Alarcón, 1995
Alarcón GS, Kremer JM, Macaluso M, et al.
MTX-lung toxicity in RA: a multicenter case control study. Arthritis Rheum 1995;
38: S205.
Al-Awadhi, 1993
Al-Awadhi A, Dale P, McKendry RJ.
Pancytopenia associated with low dose methotrexate therapy: a regional survey. J
Rheumatol 1993; 20(7): 1121-5.
Amos, 1986
Amos RS, Pullar T, Bax DE, Situnayake D,
Capell HA, McConkey B, et al. Sulphasalazine for rheumatoid arthritis: toxicity
in 774 patients monitored for one to 11 years. Br Med J Clin Res Ed 1986;
293(6544): 420-3.
Anderson, 1989
Anderson JJ, Felson DT, Meenan RF,
Williams HJ. Which traditional measures should be used in rheumatoid arthritis
clinical trials? Arthritis Rheum 1989; 32(9): 1093-9.
Anderson, 1993
Anderson JJ, Chernoff MC. Sensitivity to
change of rheumatoid arthritis clinical trial outcome measures. J Rheumatol
1993; 20(3): 535-7.
Anderson, 2000
Anderson JJ, Wells G, Verhoeven AC, Felson
DT. Factors predicting response to treatment in rheumatoid arthritis: the
importance of disease duration. Arthritis Rheum 2000; 43(1): 22-9.
Andonopoulos, 1994
Andonopoulos AP, Terzis E, Tsibri E,
Papasteriades CA, Papapetropoulos T. D-Penicillamine induced myasthenia gravis
in rheumatoid arthritis: an unpredictable common occurrence? Clin Rheumatol
1994; 13(4): 586-8.
Ansell, 1975
Ansell ID, Castro JE. Carcinoma of the
bladder complicating cyclophosphamide therapy. Br J Urol 1975; 47(4): 413-8.
Ansher, 1983
Ansher AF, Melton JW 3d, Sliwinski AJ.
Bladder malignancy in a patient receiving low dose cyclophosphamide for
treatment of rheumatoid arthritis. Arthritis Rheum 1983; 26(6): 804-5.
Appelbaum, 1976
Appelbaum F, Strauchen JA, Graw RG Jr,
Savage DD, Kent KM, Ferrans VJ, et al. Acute lethal carditis caused by high-dose
combination chemotherapy: a unique clinical and pathological entity. Lancet
1976; 1(7950): 58-62.
Aptekar, 1973
Aptekar RG, Atkinson JP, Decker JL, Wolff
SM, Chu EW. Bladder toxicity with chronic oral cyclophosphamide therapy in
nonmalignant disease. Arthritis Rheum 1973; 16(4): 461-7.
Arava, 1999
Prod Inf Arava (TM) 1999.
Arellano, 1993
Arellano F, Krupp P. Malignancies in
rheumatoid arthritis patients treated with cyclosporin A. Br J Rheumatol 1993;
32(Suppl 1): 72-5.
Arnett, 1988
Arnett FC, Edworthy SM, Bloch DA, McShane
DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised
criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;
31(3):315-24.
Asavatanabodee, 1997
Asavatanabodee P, Sholter D, Davis
P.Yttrium-90 radiochemical synovectomy in chronic knee synovitis: a one year
retrospective review of 133 treatment interventions. J Rheumatol 1997; 24(4):
639-42.
Ataya, 1993
Ataya R, Ramahi Ataya A. Reproductive
performance of female rats treated with cyclophosphamide and/or LHRH agonist.
Reprod Toxicol 1993; 7(3): 229-35.
Austin, 1986
Austin HA 3d, Klippel JH, Balow JE, Le Riche
NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis: controlled trial
of prednisone and cytotoxic drugs. N Engl J Med 1986; 314(10): 614-9.
Bacon, 1982
Bacon AM, Rosenberg SA. Cyclophosphamide
hepatotoxicity in a patient with systemic lupus erythematosus. Ann Intern Med
1982; 97(1): 61-3.
Bachman, 1996
Bachman TR, Sawitzke AD, Perkins SL, Ward
JH, Cannon GW. Methotrexate-associated lymphoma in patients with rheumatoid
arthritis: report of two cases. Arthritis Rheum 1996; 39(2): 325-9.
Bain, 1972
Bain LS, Balch HW, Wetherly JM, Yeadon A.
Intraarticular triamcinolone hexacetonide: double-blind comparison with
methylprednisolone. Br J Clin Pract 1972; 26(12): 559-61.
Baker, 1987
Baker GL, Kahl LE, Zee BC, Stolzer BL,
Agarwal AK, Medsger TA Jr. Malignancy following treatment of rheumatoid
arthritis with cyclophosphamide: long-term case-control follow-up study. Am J
Med 1987; 83(1): 1-9.
Balow, 1987
Balow JE, Austin HA 3d, Tsokos GC, Antonovych
TT, Steinberg AD, Klippel JH. NIH conference. Lupus nephritis. Ann Intern Med
1987; 106(1): 79-94.
Balsa, 1996
Balsa A, Richi P, Cabezas J, Usón J, Martín
Mola E, Gijón J. Estudio descriptivo de los 100 primeros pacientes atendidos en
una consulta de artritis de reciente comienzo. Rev Esp Reumatol, 1996; 23:
400-6.
Baltus, 1983
Baltus JA, Boersma JW, Hartman AP,
Vandenbroucke JP. The occurrence of malignancies in patients with rheumatoid
arthritis treated with cyclophosphamide: a controlled retrospective follow-up.
Ann Rheum Dis 1983; 42(4): 368-73.
Bannwarth, 1994
Bannwarth B, Labat L, Moride Y,
Schaeverbeke T. Methotrexate in rheumatoid arthritis: an update. Drugs 1994;
47(1): 25-50.
Barnes, 1994
Barnes CL, Shortkroff S, Wilson M, Sledge
CB. Intra-articular radiation treatment of rheumatoid synovitis of the ankle
with dysprosium-165 ferric hydroxide macroaggregates. Foot Ankle Int 1994;
15(6): 306-10.
Bass, 1996
Bass NM, Ockner RK. Drug-induced liver
disease. In: Zakim D, Boyer TD, editors. Hepathology: A Textbook of Liver
Disease. 3 ed. Philadelphia: WB Saunders; 1996. p. 962-1017.
Bellamy, 1998
Bellamy N, Kaloni S, Pope J, Coulter K,
Campbell J. Quantitative rheumatology: a survey of outcome measurement
procedures in routine rheumatology outpatient practice in Canada. J Rheumatol
1998; 25(5): 852-8.
Bellamy, 1999
Bellamy N, Muirden KD, Brooks PM,
Barraclough D, Tellus MM, Campbell J. A survey of outcome measurement procedures
in routine rheumatology outpatient practice in Australia. J Rheumatol 1999;
26(7): 1593-9.
Belmonte, 1988
Belmonte Serrano MA, Roig Escofet D.
Inmunomoduladores. Tratamiento (V). In: Roig Escofet D., editor. Artritis
reumatoide. Barcelona: Doyma; 1988. p. 226-34.
Benson, 1974
Benson TB, Copp EP. The effects of
therapeutic forms of heat and ice on the pain threshold of the normal shoulder.
Rheumatol Rehabil 1974; 13(2): 101-4.
Berg, 1989
Berg KJ, Forre O, Djoseland O, Mikkelsen M,
Narverud J, Rugstad HE. Renal side effects of high and low cyclosporin A doses
in patients with rheumatoid arthritis. Clin Nephrol 1989; 31(5): 232-8.
Berglund, 1993
Berglund K, Thysell H, Keller C. Results,
principles and pitfalls in the management of renal AA-amyloidosis: a 10-21 year
followup of 16 patients with rheumatic disease treated with alkylating
cytostatics. J Rheumatol 1993; 20(12): 2051-7.
Bird, 1979
Bird HA, Ring EF, Bacon PA. A thermographic
and clinical comparison of three intra-articular steroid preparations in
rheumatoid arthritis. Ann Rheum Dis 1979; 38(1): 36-9.
Bird, 1990
Bird HA. Drugs and the elderly. Ann Rheum Dis
1990; 49(12): 1021-4.
Birnie, 1981
Birnie GG, McLeod TI, Watkinson G. Incidence
of sulphasalazine-induced male infertility. Gut 1981; 22(6): 452-5.
Bitter, 1984
Bitter, T. Combined disease-modifying
chemotherapy for intractable rheumatoid arthritis. Clin Rheum Dis
1984;10:417-28
Black, 1998
Black AJ, McLeod HL, Capell HA, Powrie RH,
Matowe LK, Pritchard SC, et al. Thiopurine methyltransferase genotype predicts
therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998; 129(1):
716-8.
Blanco, 1996
Blanco R, Martínez Taboada VM, González Gay
MA, Armona J, Fernández Sueiro JL, Gonzalez Vela MC, et al. Acute febrile toxic
reaction in patients with refractory rheumatoid arthritis who are receiving
combined therapy with methotrexate and azathioprine. Arthritis Rheum 1996;
39(6): 1016-20.
Blyth, 1994
Blyth T, Hunter JA, Stirling A. Pain relief
in the rheumatoid knee after steroid injection: a single-blind comparison of
hydrocortisone succinate, and triamcinolone acetonide or hexacetonide. Br J
Rheumatol 1994; 335): 461-3.
Boers, 1988
Boers M, van Rijthoven AW, Goei The HS,
Dijkmans BA, Cats A. Serum creatinine levels two years later: follow-up of a
placebo-controlled trial of cyclosporin in rheumatoid patients. Transplant Proc
1988; 20(3 Suppl 4): 371-5.
Boers, 1990
Boers M, Dijkmans BA, van Rijthoven AW, Goei
The HS, Cats A. Reversible nephrotoxicity of cyclosporin in rheumatoid
arthritis. J Rheumatol 1990: 17(1): 38-42.
Boers, 1994
Boers M, Tugwell P, Felson DT, van Riel PL,
Kirwan JR, Edmonds JP, et al. World Health Organization and International League
of Associations for Rheumatology core endpoints for symptom modifying
antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol 1994;
21(Suppl 41): 86-9.
Boers, 1997
Boers M,Verhoeven AC, Markusse HM, van de
Laar MA, Westhovens R, van Denderen JC, van Zeben C, et al. Randomised
comparison of combined step-down prednisolone, methotrexate and sulphasalazine
with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350(9074):
309-18.
Bogoch, 1999.
Bogoch ER, Moran EL. Bone abnormalities in
the surgical treatment of patients with rheumatoid arthritis. Clin Orthop 1999;
(366): 8-21.
Bontoux, 1978
Bontoux D, Alcalay M, Reboux JF, Puthon A.
Synoviortheses du genou par l’acide osmique: a propos de 61 injections. Rev Rhum
Mal Osteoartic 1978; 45(2): 101-5.
Boumpas, 1993
Boumpas DT, Austin HA 3d, Vaughan EM,
Yarboro CH, Klippel JH, Balow-JE. Risk for sustained amenorrhea in patients with
systemic lupus erythematosus receiving intermittent pulse cyclophosphamide
therapy. Ann Intern Med 1993; 119(5): 366-9.
Boyer, 1989.
Boyer DL, Li BU, Fyda JN, Friedman RA.
Sulphasalazine-induced hepatotoxicity in children with inflammatory bowel
disease. J Pediatr Gastroenterol Nutr 1989; 8(4): 528-32.
Bradley, 1989
Bradley JD, Brandt KD, Katz BP. Infectious
complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum
1989; 32(1): 45-53.
Breedveld, 1989
Breedveld FC, Markusse HM, MacFarlane JD.
Subcutaneous fat biopsy in the diagnosis of amyloidosis secondary to chronic
arthritis. Clin Exp Rheumatol 1989; 7(4): 407-10.
Brennan, 1996
Brennan P, Harrison B, Barrett E,
Chakravarty K, Scott D, Silman A, et al. A simple algorithm to predict the
development of radiological erosions in patients with early rheumatoid
arthritis: prospective cohort study. BMJ 1996; 313(7055): 471-6.
Bressler, 1985
Bressler RB, Huston DP. Water intoxication
following moderate-dose intravenous cyclophosphamide. Arch Intern Med 1985;
145(3): 548-9.
Bretza, 1983
Bretza J, Wells I, Novey HS. Association of
IgE antibodies to sodium aurothiomalate and adverse reactions to chrysotherapy
for rheumatoid arthritis. Am J Med 1983; 74(6): 945-50.
Bridges, 1991
Bridges SL Jr, Lopez Mendez A, Han KH,
Tracy IC, Alarcon GS. Should methotrexate be discontinued before elective
orthopedic surgery in patients with rheumatoid arthritis? J Rheumatol 1991;
18(7): 984-8.
Brock, 1982
Brock N, Pohl J, Stekar J, Scheef W. Studies
on the urotoxicity of oxazaphosphorine cytostatics and its prevention. III.
Profile of action of sodium 2-mercaptoethane sulfonate (mesna). Eur J Cancer
Clin Oncol 1982; 18(12): 1377-87.
Brook, 1977
Brook A, Fleming A, Corbett M. Relationship
of radiological change to clinical outcome in rheumatoid arthritis. Ann Rheum
Dis 1977; 36(3): 274-5.
Brook, 1990
Brook RH. Quality assessment and technology
assessment: critical linkages. In: Lohr KN, Rettig RA, editors. Qualtity of care
and technology assessment. Washington, D.C.: National Academy Press; 1990. p.
21-8.
Brook, 1991
Brook RH. Quality of care: do we care? Ann
Intern Med 1991; 115(6): 486-90.
Bryant, 1980
Bryant BM, Jarman M, Ford HT, Smith IE.
Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane
sulphonate sodium (mesnum) in patients with advanced carcinoma. Lancet 1980;
2(8196): 657-9.
Buchan, 1991
Buchan IE, Bird HA. Drug interactions in
arthritic patients. Ann Rheum Dis 1991; 50(10): 680-1.
Buchbinder, 1995
Buchbinder R, Bombardier C, Yeung M,
Tugwell P. Which outcome measures should be used in rheumatoid arthritis
clinical trials?: clinical and quality-of-life measures' responsiveness to
treatment in randomized controlled trial. Arthritis Rheum 1995; 38(11):
1568-80.
Burstin, 1993
Burstin HR, Lipsitz SR, Udvarhelyi IS,
Brennan TA. The effects of hospital financial characteristics on quality of
care. JAMA 1993; 270(7): 845-9.
Cairns, 1992
Cairns HS, Neild G. Cyclosporin
nephrotoxicity. In: Cameron S, Davison AM, Grünfeld JP, et al., editors. Oxford
Textbook of Clinical Nephrology. Oxford: Oxford University Press; 1992. p.
1560-9.
Caldwell, 1991
Caldwell JR, Furst DE. The efficacy and
safety of low-dose corticosteroids for rheumatoid arthritis. Semin Arthritis
Rheum 1991; 21(1): 1-11.
Camussi, 1998
Camussi G, Lupia E. The future role of
anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid
arthritis. Drugs 1998; 55(5): 613-20.
Cannon, 1997
Cannon GW. Methotrexate pulmonary toxicity.
Rheum Dis Clin North Am 1997; 23(4): 917-37.
Canvin, 1993
Canvin JM, El Gabalawy HS, Chalmers MI.
Fatal agranulocytosis with sulfasalazine therapy in rheumatoid arthritis. J
Rheumatol 1993; 20(5): 909-10.
Carpenter, 1996
Carpenter MT, West SG, Vogelgesang SA,
Casey Jones DE. Postoperative joint infections in rheumatoid arthritis patients
on methotrexate therapy. Ortthopedics 1996; 19(3): 207-10.
Castillo, 1965
Castillo BA, el-Sallab RA, Scott JT.
Physical activity, cystic erosion, and osteoporosis in rheumatoid arthritis. Ann
Rheum Dis 1965; 24(6): 522-7.
CCOHTA, 1999
The Canadian Coordinating Office for Health
Technology Assessment. Etanercept: anti-tumor necrosis factor therapy for
rheumatoid arthritis. Issues in Emerging Health Technologies 1999; Issue 8,
Oct.
Chakravarty, 1994
Chakravarty K, Pharoah PD, Scott DG. A
randomized controlled study of post-injection rest following intra-articular
steroid therapy for knee synovitis. Br J Rheumatol 1994; 33(5): 464-8.
Chalmers, 1982
Chalmers A, Thompson D, Stein HE, Reid G,
Patterson AC. Systemic lupus erythematosus during penicillamine therapy for
rheumatoid arthritis. Ann Intern Med 1982; 97(5): 659-63.
Chapman, 1981
Chapman RM, Sutcliffe SB. Protection of
ovarian function by oral contraceptives in women receiving chemotherapy for
Hodgkin´s disease. Blood. 1981; 58(4): 849-51.
Chassin, 1991
Chassin MR. Quality of care. Time to act.
JAMA 1991; 266(24): 3472-3.
Clements, 1986
Clements PJ, Davis J. Cytotoxic drugs:
their clinical application to the rheumatic diseases. Semin Arthritis Rheum
1986; 15(4): 231-54.
Clunie, 1996
Clunie G, Lui D, Cullum I, Ell PJ, Edwards
JC. Clinical outcome after one year following samarium-153 particulate
hydroxyapatite radiation synovectomy. Scand J Rheumatol 1996; 25(6): 360-6.
Cohen, 1992
Cohen DJ, Appel GB. Cyclosporin: nephrotoxic
effects and guidelines for safe use in patients with rheumatoid arthritis. Semin
Arthritis Rheum 1992; 21(6 Suppl 3): 43-8.
Conaty, 1971
Conaty JP, Nikel VL. Functional
incapacitation in rheumatoid arthritis: a rehabilitation challenge: a
correlative study of function before and after hospital treatment. J Bone Joint
Surg Am 1971; 53(4): 624-37.
Creighton, 1998
Creighton MG, Callaghan JJ, Olegniczak
JP, Johnson RC. Total hip arthroplasty with cement in patients who have
rheumatoid arthritis: a minimum ten-year follow-up study. J Bone Joint Surg
1998; 80(10): 1439-46.
Criswell, 2000
Criswell LA, Saag KG, Sems KM, Welch V,
Shea B, Wells G, Suarez-Almazor ME Moderate-term, low-dose corticosteroids for
rheumatoid arthritis. Cochrane Database Syst Rev 2000; (2): CD001158.
Cush, 1999
Cush JJ, Tugwell P, Weimblatt M, Yocum D. US
consensus guidelines for the use of cyclosporin A in rheumatoid arthritis. J
Rheumatol 1999; 26(5): 1176-86.
Dahl, 1990
Dahl SL, Samuelson CO, Williams HJ, Ward JR,
Karg M. Second-line antirheumatic drugs in the elderly with rheumatoid
arthritis: a post hoc analysis of three controlled trials. Pharmacotherapy 1990;
10(2): 79-84.
Damewood, 1986
Damewood MD, Grochow LB. Prospects for
fertility after chemotherapy or radiation for neoplastic disease. Fertil Steril
1986, 45(4): 443-59.
David, 1993
David J, Vouyiouka O, Ansell BM, Hall A, Woo
P. Amyloidosis in juvenile chronic arthritis: a morbidity and mortality study.
Clin Exp Rheumatol 1993; 11(1): 85-90.
Davis, 1974
Davis P, Hughes GR. Significance of
eosinophilia during gold therapy. Arthritis Rheum 1974; 17(6): 964-8.
Dawes, 1986
Dawes PT, Fowler PD, Clarke S, Fisher J,
Lawton A, Shadforth MF. Rheumatoid arthritis: treatment which controls the C-
reactive protein and erythrocyte sedimentation rate reduces radiologic
progression. Br J Rheumatol 1986; 25(1): 44-9.
De Fronzo, 1973
DeFronzo RA, Braine H, Colvin M, Davis
PJ. Water intoxication in man after cyclophosphamide therapy. Time course and
relation to drug activation. Ann Intern Med 1973; 78(6): 861-9.
Deandrade, 1965
Deandrade JR, Casagrande PA. A seven-day
variability study of 499 patients with peripheral rheumatoid arthritis.
Arthritis Rheum 1965; 19: 302-34.
Decker, 1973
Decker JL. Toxicity of immunosuppressive
drugs in man. Arthritis Rheum 1973; 16(1): 89-91.
Donabedian, 1980
Donabedian A. Explorations in quality
assessment and monitoring. Ann Arbor, MI: Health Administration Press; 1980.
Donabedian, 1988
Donabedian A. The assessment of
technology and quality: a comparative study of certainties and ambiguities. Int
J Technol Assess Health Care 1988; 4(4): 487-96.
Dougados, 1989
Dougados M, Duchesne L, Awada H, Amor B.
Assessment of efficacy and acceptability of low dose cyclosporin in patients
with rheumatoid arthritis. Ann Rheum Dis 1989; 48(7): 550-6.
Dreyer, 1999
Dreyer SJ, Boden SD. Natural history of
rheumatoid arthritis of the cervical spine. Clin Orthop1999; (366): 98-106.
Drossaers-Bakker, 1999
Drossaers-Bakker KW, de Buck M,
van Zeben D, Zwinderman AH, Breedveld FC, Hazes JM. Long-term course and outcome
of functional capacity in rheumatoid arthritis: The effect of disease activity
and radiologic damage over time. Arthritis Rheum 1999; 42(9): 1854-60.
Drugex, 1999
Drugex® Ed. Staff. Drugex Information
System. Micromedex Inc. Denver, Colorado. Vol. 101, 1999: Sulphasalazine.
Dunbar, 1998
Dunbar RP, Alexiades MM. Decision making in
rheumatoid arthritis. Determining surgical priorities. Rheum Dis Clin North Am
1998; 24(1): 35-54.
Duston, 1989
Duston MA, Skinner M, Meenan RF, Cohen AS.
Sensitivity, specificity, and predictive value of abdominal fat aspiration for
the diagnosis of amyloidosis. Arthritis Rheum 1989; 32(1): 82-5.
Eberhardt, 1998
Eberhardt K, Fex E. Clinical course and
remission rate in patients with early rheumatoid arthritis: relationship to
outcome after 5 years. Br J Rheumatol 1998; 37(12): 1324-9.
Edmonds, 1999
Edmonds J, Saudan A, Lassere M, Scott D.
Introduction to reading radiographs by the Scott modification of the Larsen
method. J Rheumatol 1999; 26(3): 740-2.
Ehrlich, 1982
Ehrlich GE. Heroic treatment for
nonmalignant diseases. J Am Med Assoc 1982;248:1743-4.
Ehrlich, 1984
Ehrlich RM, Freedman A, Goldsobel AB,
Stiehm ER. The use of sodium-2-mercaptoethane sulfonate to prevent
cyclophosphamide cystitis. J Urol 1984; 131(5): 960-2.
Ekblom, 1975a
Ekblom B, Lovgren O, Alderin M, Fridstrom
M, Satterstrom G. Effect of short-term physical training on patients with
rheumatoid arthritis I. Scand J Rheumatol 1975; 4(2): 80-6.
Ekblom, 1975b
Ekblom B, Lovgren O, Alderin M, Fridstrom
M, Satterstrom G. Effect of short-term physical training on patients with
rheumatoid arthritis: a six-month follow-up study. Scand J Rheumatol 1975; 4(2):
87-91.
Ellman, 1991
Ellman MH, Hurwitz H, Thomas C, Kozloff M.
Lymphoma developing in a patient with rheumatoid arthritis taking low dose
weekly methotrexate. J Rheumatol 1991; 18(11): 1741-3.
Emery, 1999
Emery P, Zeidler H, Kvien TK, Guslandi M,
Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of
rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;
354(9196): 2106-11.
Erickson, 1995
Erickson AR, Reddy V, Vogelgesang SA, West
SG. Usefulness of the American College of Rheumatology recommendations for liver
biopsy in methotrexate-treated rheumatoid arthritis patients. Arthritis Rheum
1995; 38(8): 1115-9.
Escalante, 1999
Escalante A, Rincon I. How much
disability in rheumatoid arthritis is explained by rheumatoid arthritis?
Arthritis Rheum 1999; 42(8): 1712-21.
Esteve- Vives, 1993
Esteve Vives J, Batlle Gualda E, Reig
A. Spanish version of the Health Assessment Questionnaire (HAQ): reliability,
validity and transcultural equivalency. Grupo para la Adaptación del HAQ a la
Población Española. J Rheumatol 1993; 20(12): 2116-22.
Esteve-Vives, 1994
Esteve-Vives J, Batlle-Gualda E,
Tornero J, Tenorio M, Boquet D, Martínez-Sanchís A. Adaptación del Modified
Health Assessment Questionnaire (MHAQ) a la población española. Rev Esp Reumatol
1994; 21: 165.
Fairley, 1972
Fairley KF, Barrie JU, Johnson W. Sterility
and testicular atrophy related to cyclophosphamide therapy. Lancet 1972;
1(7750): 568-9.
Farr, 1986
Farr M, Scott DG, Bacon PA. Side effect
profile of 200 patients whit inflammatory arthritis treated with sulphasalazine.
Drugs 1986; 32 (Suppl 1): 49-53.
Farrell, 1998
Farrell GC. Liver disease caused by drugs,
anesthetics, and toxins. In: Feldman M, Scharschmidt BF, Sleisenger MH, editors.
Gastrointestinal and Liver Disease. 6 ed. Philadelphia: WB Saunders; 1998. p.
1221-53.
Fauci, 1983
Fauci AS, Haynes BF, Katz P, Wolf SM.
Wegener´s granulomatosis: prospective clinical and therapeutic experience with
85 patients over 21 years. Ann Intern Med 1983; 98(1): 76-85.
Fauci, 1989
Fauci AS, Young KR Jr. Immunoregulatory
agents. In: Kelley WN, Harris ED, Ruddy S, Sledge CB, editors. Textbook of
Rheumatology. 3 ed. Philadelphia: WB Saunders; 1989. p. 862-88.
Fauci, 1993
Fauci AS, Randall KY. Immunoregulatory
agents. In: Kelley W, Harris E, Ruddy S, Sledge CB, editors. Textbook of
Rheumatology. Philadelphia: WB Saunders; 1993. p. 797-821.
Feibel, 1976
Feibel A, Fast A. Deep heating of joints: a
reconsideration. Arch Phys Med Rehab 1976; 57(11): 513-4.
Felson, 1993a
Felson DT. Choosing a core set of disease
activity measures for rheumatoid arthritis clinical trials. J Rheumatol 1993;
20(3): 531-4.
Felson, 1993b
Felson DT, Anderson JJ, Boers M, Bombardier
C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary
core set of disease activity measures for rheumatoid arthritis clinical trials.
The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials.
Arthritis Rheum 1993; 36(6): 729-40.
Felson, 1994
Felson DT, Anderson JJ, Meenan RF. The
efficacy and toxicity of combination therapy in rheumatoid arthritis. A
meta-analysis. Arthritis Rheum 1994; 37(10): 1487-91.
Felson, 1995
Felson DT, Anderson JJ, Boers M, Bombardier
C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary
definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38(6):
727-35.
Ferraz, 1990
Ferraz MB, Quaresma MR, Aquino LR, Atra E,
Tugwell, Goldsmith CH. Reliability of pain scales in the assessment of literate
and illiterate patients with rheumatoid arthritis. J Rheumatol 1990; 17(8):
1022-4.
Finbloom, 1985
Finbloom D, Silver K, Newsome DA, Gunkel
R. Comparison of hydroxychloroquine and chloroquine use and the development of
retinal toxicity. J Rheumatol 1985; 12(4): 692-4.
Fisher, 1996
Fisher CJ Jr, Agostini JM, Opal SM, Lowry
SF, Blak RA, Sadoff JC, et al. Treatment of septic shock with tumor necrosis
factor receptor: Fc fusion protein. N Engl J Med 1996; 334(26): 1697-702.
Fizpatrick, 1991
Fitzpatrick R, Newman S, Archer R,
Shipley M. Social support, disability and depression: a longitudinal study of
rheumatoid arthritis. Soc Sci Med 1991; 33(5): 605-11.
Forre, 1994
Forre O. Radiologic evidence of disease
modification in rheumatoid arthritis patients treated with cyclosporine. Results
of a 48-week multicenter study comparing low-dose cyclosporine with placebo.
Arthritis Rheum 1994; 37(10): 1506-12.
Fosdick, 1968
Fosdick WM, Parsons JL, Hill DF. Long-term
cyclophosphamide therapy in rheumatoid arthritis. Arthritis Rheum 1968; 11(2):
151-61.
Fox, 1994
Fox DA, McCune WJ. Immunosuppressive drug
therapy of systemic lupus erythematosus. Rheum Dis Clin North Am. 1994; 20(1):
265-99.
Fries, 1980
Fries JF, Spitz P, Kraines RG, Holman HR.
Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23(2):
137-45.
Fries, 1996
Fries JF, Williams CA, Morfeld D, Singh G,
Sibley J Reduction in long-term disability in patients with rheumatoid arthritis
by disease-modifying antirheumatic drug-based treatment strategies. Arthritis
Rheum, 1996; 39(4): 616-22.
Fuchs, 1989
Fuchs HA, Brooks RH, Callahan LF, Pincus T. A
simplified twenty-eight-joint quantitative articular index in rheumatoid
arthritis. Arthritis Rheum 1989; 32(5): 531-7.
Fuchs, 1994
Fuchs HA, Pincus T. Reduced joint counts in
rheumatoid arthritis clinical trials. Arthritis Rheum 1994; 37(4): 470-5.
Furst, 1990
Furst DE. Proposition: methotrexate should
not be the first second-line agent to be used in rheumatoid arthritis if NSAIDs
fail. Semin Arthritis Rheum 1990; 20(2): 69-75.
Furst, 1994a
Furst DE. Predictors of worsening clinical
variables and outcomes in rheumatoid arthritis. Rheum Dis Clin North Am 1994;
20(2): 309-19.
Furst, 1994b
Furst DE, Clements PJ. SAARDs. II.
Pharmacologic approaches. In: Klippel JH, Dieppe PA, editors. Rheumatology.
London: Mosby; 1994. p. 8: 13.1-13.8.
Furst, 1995
Furst DE. Innovative treatment approaches for
rheumatoid arthritis: cyclosporin, leflunomide and nitrogen mustard. Baillieres
Clin Rheumatol 1995; 9(4): 711-29.
Gates, 1993
Gates PE. Clinical quality improvement:
getting physicians involved. QRB Qual Rev Bull 1993; 19(2): 56-61.
Gertz, 1991
Gertz MA, Kyle RA. Secondary systemic
amyloidosis: response and survival in 64 patients. Medicine (Baltimore) 1991;
70(4): 246-56.
Gibson, 1987
Gibson T, Emery P, Armstrong RD, Crisp AJ,
Panayi GS. Combined D-penicillamine and chloroquine treatment of rheumatoid
arthritis -a comparative study. Br J Rheumatol 1987; 26:279-84.
Glave Testino, 1994
Glave Testino C, Cardiel M, Arce
Salinas A, Alarcon Segovia D. Factors associated with disease severity in
Mexican patients with rheumatoid arthritis. Clin Exp Rheumatol 1994; 12(6):
589-94.
Glenner, 1980
Glenner GG. Amyloid deposits and
amyloidosis: the beta-fibrilloses (first of two parts). N Engl J Med 1980;
302(23): 1283-92.
Goldberg, 1985
Goldberg JW, Lidsky MD.
Cyclophosphamide-associated hepatotoxicity. South Med J 1985; 78(2): 222-3.
Golden, 1995
Golden MR, Katz RS, Balk RA, Golden HE. The
relationship of preexisting lung disease to the development of methotrexate
pneumonitis in patients with rheumatoid arthritis. J Rheumatol 1995; 22(6):
1043-7.
Gordon, 1973
Gordon DA, Stein JL, Broder I. The
extra-articular features of rheumatoid arthritis: a systematic analysis of 127
cases. Am J Med 1973; 54(4): 445-52.
Gotzsche, 2000a
Gotzsche PC. Non-steroidal
anti-inflammatory drugs. BMJ 2000; 320(7241): 1058-61.
Gotzsche, 2000b
Gotzsche PC, Johansen HK Short-term
low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in
rheumatoid arthritis Cochrane Database Syst Rev 2000; (2): CD000189.
Grant, 1987
Grant D, Wall W, Duff J, Stiller C, Ghent C,
Keown P. Adverse effects of cyclosporin therapy following liver transplantation.
Transplant Proc 1987; 19(4): 3463-5.
Grassi, 2001
Grassi W, Filippucci E, Farina A, Salaffi F,
Cervini C. Ultrasonography in the evaluation of bone erosions. Ann Rheum Dis
2001; 60(2): 98-104.
Greene, 1986
Greene MH, Harris EL, Gershenson DM,
Malkasian GD Jr, Melton LJ 3d, Dembo AJ, et al. Melphalan may be a more potent
leukemogen than cyclophosphamide. Ann Intern Med 1986; 105(3): 360-7.
Grob, 1999
Grob D, Schutz V, Plotz G. Occipitocervical
fusion in patients with rheumatoid arthritis. Clin Orthop 1999; (366):
46-53.
Grunwald, 1979
Grunwald HW, Rosner F. Acute leukemia and
immunosuppressive drug use: a review of patients undergoing immunosuppressive
therapy for non-neoplastic diseases. Arch Intern Med 1979; 139(4): 461-6.
Guillemin, 1989
Guillemin F, Aussedat R, Guerci A,
Lederlin P, Trechot P, Pourel J. Fatal agranulocytosis in sulphasalazine treated
rheumatoid arthritis. J Rheumatol 1989; 16(8): 1166-7.
Gulley, 1979
Gulley RM, Mirza A, Kelly CE. Hepatotoxicity
of salicylazosulphapyridine: a case report and review of the literature. Am J
Gastroenterol 1979; 72(5): 561-4.
Gumpel, 1979
Gumpel JM, Matthews SA, Fisher M.
Synoviorthesis with erbium-169: a double-blind controlled comparison of
erbium-169 with corticosteroid. Ann Rheum Dis 1979; 38(4): 341-3.
Gutiérrez-Ureña, 1996
Gutierrez Ureña S, Molina JF,
García CO, Cuellar ML, Espinoza LR. Pancytopenia secondary to methotrexate
therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39(2): 272-6.
Haagsma, 1997
Haagsma CJ, van Riel, de Jong AJ, van de
Putte LB. Combination of sulphasalazine and methotrexate versus the single
components in early rheumatoid arthritis: a randomized, controlled,
double-blind, 52 week clinical trial. Br J Rheumatol 1997; 36:1082-8.
Hadorn, 1996
Hadorn DC, Baker D, Hodges JS, Hicks N.
Rating the quality of evidence for clinical practice guidelines. J Clin
Epidemiol 1996; 49(7): 749-54.
Hall, 1988a
Hall CL, Jawad S, Harrison PR, MacKenzie JC,
Bacon PA, Klouda PT, et al. Natural course of penicillamine nephropathy: a long
term study of 33 patients. Br Med J 1988; 296(6629): 1083-6.
Hall, 1988b
Hall CL. Gold nephropathy. Nephron 1988;
50(4): 267-72.
Halla, 1994
Halla JT, Hardin JG. Underrecognized
postdosing reactions to methotrexate in patients with rheumatoid arthritis. J
Rheumatol 1994; 21(7): 1224-6.
Hansen, 1983
Hansen SE. Carcinoma of the bladder in a
patient treated with cyclophosphamide for rheumatoid arthritis. Scand J
Rheumatol 1983; 12(2): 73-4.
Hargreaves, 1992
Hargreaves MR, Mowat AG, Benson MK.
Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid
arthritis: report of five cases and review of published reports. Thorax 1992;
47(8): 628-33.
Hargreaves, 1999
Hargreaves D, Emery R. Total elbow
replacement in the treatment of rheumatoid disease. Clin Orthop 1999; (366):
61-71.
Harris, 1974
Harris ED Jr, McCroskery PA. The influence
of temperature and fibril stability on degradation of cartilage collagen by
rheumatoid synovial colagenase. N Engl J Med 1974; 290(1): 1-6.
Harris, 1983
Harris ED, Emkey RD, Nichols JE, Newberg A.
Low dose prednisone therapy in rheumatoid arthritis: a double blind study. J
Rheumatol 1983: 10(5): 713-21.
Harrison, 1996
Harrison BJ, Symmons DP, Brennan P,
Barrett EM, Silman AJ. Natural remission in inflammatory polyarthritis: issues
of definition and prediction. Br J Rheumatol 1996; 35(11): 1096-100.
Hayward, 1993
Hayward RA, Bernard AM, Rosevear JS,
Anderson JE, McMahon LF. An evaluation of generic screens for poor quality of
hospital care on a general medicine service. Med Care 1993; 31(5): 394-402.
Hazenberg, 1994
Hazenberg BP, van Rijswijk MH. Clinical
and therapeutic aspects of AA amyloidosis. Baillieres Clin Rheumatol 1994; 8(3):
661-90.
Hazes, 1994
Hazes JMW, Cats A. In: Klippel JH, Dieppe PA,
editors. Rheumatology. London: Mosby; 1994. p. 3: 14.1-14.8.
Healey, 1986
Healey LA. Rheumatoid arthritis in the
elderly. Clin Rheum Dis 1986; 12(1): 173-9.
Hernández-García, 2000
Hernández-García C, Vargas E,
Abasolo L, Lajas C, Bellarjdell B, Morado IC, Macarrón P, Pato E,
Fernández-Gutiérrez B, Bañares A, Jover JA. Long-time between a set of symptoms
and access to rheumatology care and DMARDs therapy in a cohort of patients with
rheumatoid arthritis. J Rheumatol 2000; 27: 2323-28.
Hernández-García, 2001
Hernández-García C,
González-Alvaro I, Villaverde V, Vargas E, Jover JA, Lázaro P y el Grupo de
Estudio emAR. Estudio sobre el manejo de la rheumatoid arthritis en España.
Sociedad Española de Reumatología. Madrid, 2001.
Hickling, 1998
Hickling P, Jacoby RK, Kirwan JR. Joint
destruction after glucocorticoids are withdrawn in early rheumatoid arthritis.
Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Br J
Rheumatol 1998; 37(9): 930-6.
Hilsden, 1995
Hilsden RJ, Urbanski SJ, Swain MG.
End-stage liver disease developing with the use of methotrexate in heterozygous
alfa1-antitrypsin deficiency. Arthritis Rheum 1995; 38(7): 1014-8.
Hoffman, 1992
Hoffman GS, Kerr GS, Leavitt RY, Hallahan
CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158
patients. Ann Intern Med 1992; 116(6): 488-98.
Howard, 1986
Howard Lock HE, Lock CJ, Mewa A, Kean WF.
D-penicillamine: chemistry and clinical use in rheumatic disease. Semin
Arthritis Rheum 1986; 15(4): 261-81.
Hows, 1984
Hows JM, Mehta A, Ward L, Woods K, Perez R,
Gordon MY, et al. Comparison of mesna with forced diuresis to prevent
cyclophosphamide induced haemorrhagic cystitis in marrow transplantation: a
prospective randomised study. Br J Cancer 1984; 50(6): 753-6.
Hulsmans, 2000
Hulsmans HM, Jacobs JW, van der Heijde DM,
van Albada-Kuipers GA, Schenk Y, Bijlsma JW. The course of radiologic damage
during the first six years of rheumatoid arthritis. Arthritis Rheum 2000; 43(9):
1927-40.
Hurwitz, 1969
Hurwitz N. Predisposing factors in adverse
reactions to drugs. Br Med J 1969; 1(643): 536-9.
Husby, 1985
Husby G. Amyloidosis and rheumatoid
arthritis. Clin Exp Rheumatol 1985; 3(2): 173-80.
Hutter, 1969
Hutter AM Jr, Bauman AW, Frank IN.
Cyclophosphamide and severe hemorrhagic cystitis. N Y State J Med 1969; 69(2):
305-9.
IOM, 1990a
Field MJ, Lohr KN, editors. Clinical Practice
Guidelines: Directions for a New Program. Washington, D.C.: National Academy
Press; 1990.
IOM, 1990b
Lohr KN, editor. Medicare: A strategy for
quality assurance. Washington, D.C.: National Academy Press; 1990.
IOM, 1992
Field MJ, Lohr KN, editors. Guidelines for
Clinical Practice: from Development to Use. Washington, D.C.: National Academy
Press; 1992.
Jack, 1981
Jack MK, Hicks JD. Ocular complications in
high-dose chemotherapy and marrow transplantation. Ann Ophtalmol 1981; 13(6):
709-11.
Jadad, 1996a
Jadad AR, Moore RA, Carroll D, Jenkinson C,
Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of
randomized clinical trials: is blinding necessary? Control Clin Trials
1996;17(1):1-12.
Jadad, 1996b
Jadad AR, McQuay HJ. Meta-analyses to
evaluate analgesic interventions: a systematic qualitative review of their
methodology. Clin Epidemil 1996; 49(2): 235-43.
Jaffe, 1977
Jaffe IA. D-penicillamine. Bull Rheum Dis
1977-78; 28(6): 948-52.
Jahangier, 1997
Jahangier ZN, Jacobs JW, van Isselt JW,
Bijlsma JW. Persistent synovitis treated with radiation synovectomy using
yttrium-90: a retrospective evaluation of 83 procedures for 45 patients. Br J
Rheumatol 1997; 36(8): 861-9.
Jaison, 1970
Jaison MI, Rubenstein D, Dixon AS.
Intra-articular pressure and rheumatoid geodes (bone 'cysts'). Ann Rheum Dis
1970; 2985): 496-502.
Jantti, 1999
Jantti J, Aho K, Kaarela K, Kautiainen H.
Work disability in an inception cohort of patients with seropositive rheumatoid
arthritis: a 20 year study. Rheumatology 1999; 38(11): 1138-41.
Johnson, 1971
Johnson WW, Meadows DC. Urinary-bladder
fibrosis and telangiectasia associated with long-term cyclophosphamide therapy.
N Engl J Med 1971; 284(6): 290-4.
Jones, 1993
Jones G. Yttrium synovectomy: a meta-analysis
of the literature. Aust N Z J Med 1993; 23(3): 272-5.
Jurik, 1982
Jurik AG, Davidsen D, Graudal H. Prevalence
of pulmonary involvement in rheumatoid arthritis and its relationship to some
characteristics of the patients: a radiological and clinical study. Scand J
Rheumatol 1982; 11(4): 217-24.
Jurik, 1986
Jurik AG, Graudal H. Pericarditis in
rheumatoid arthritis: a clinical and radiological study. Rheumatol Int 1986;
6(1): 37-42.
Kahn, 1990
Kahn KL, Rogers WH, Rubenstein LV, Sherwood
MJ, Reinish EJ, Keeler EB, et al. Measuring quality of care with explicit
process criteria before and after implementation of the DRG-based prospective
payment system. JAMA 1990; 264(15): 1969-73.
Kamel, 1993
Kamel OW, van de Rijn M, Weiss LM, Del Zoppo
GJ, Hench PK, Robbins BA, et al. Brief report: reversible lymphomas associated
with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid
arthritis and dermatomyositis. N Engl J Med 1993; 328(18): 1317-21.
Kanik, 1997
Kanik KS, Cash JM. Does methotrexate increase
the risk of infection or malignancy? Rheum Dis Clin North Am 1997; 23(4):
955-67.
Kaplinsky, 1978
Kaplinsky N, Frankl O.
Salicylazosulphapyridine-induced Heinz body anemia. Acta Haematol 1978; 59(5):
310-4.
Karam, 1994
Karam NE, Roger L, Hankins LL, Reveille JD.
Rheumatoid nodulosis of the meninges. J Rheumatol 1994; 21(10): 1960-3.
Kassirer, 1993
Kassirer JP. The quality of care and the
quality of measuring it. N Engl J Med 1993; 329(17): 1263-5.
Kattwinkel, 1991
Kattwinkel N, Cook L, Agnello V.
Overwhelming fatal infection in a young woman after intravenous cyclophosphamide
therapy for lupus nephritis. J Rheumatol 1991; 18(1): 79-81.
Kaye, 1987
Kaye JJ, Callahan LF, Nance EP Jr, Brooks RH,
Pincus T. Rheumatoid arthritis: explanatory power of specific radiographic
findings for patient clinical status. Radiology 1987; 165(3): 753-8.
Keeler, 1992
Keeler EB, Rubenstein LV, Kahn KL, Draper D,
Harrison ER, McGinty MJ, et al. Hospital characteristics and quality of care.
JAMA 1992; 268(13): 1709-14.
Kelly, 1993
Kelly CA. Rheumatoid arthritis: other
rheumatoid lung problems. Baillieres Clin Rheumatol 1993; 7(1): 17-29.
Kende, 1979
Kende G, Sirkin S, Thomas PR, Freeman AI.
Blurring of vision: a previously undescribed complication of cyclophosphamide
therapy. Cancer 1979; 44(1): 69-71.
Kerstens, 1992
Kerstens PJ, Boerbooms AMT, Jeurissen ME,
Fast JH, Assmann KJ, van de Putte LB. Accelerated nodulosis during low dose
methotrexate therapy for rheumatoid arthritis: an analysis of ten cases. J
Rheumatol 1992; 19(6): 867-71.
Kingsmore, 1992
Kingsmore SF, Hall BD, Allen NB, Rice JR,
Caldwell DS. Association of methotrexate, rheumatoid arthritis and lymphoma:
report of two cases and literature review. J Rheumatol 1992; 19(9): 1462-5.
Kirsner, 1982
Kirsner AB, Farber SJ, Sheon RP, Finkel RI.
The incidence malignant disease in patients receiving cytotoxic therapy for
rheumatoid arthritis. Ann Rheum Dis 1982; 41(Suppl 1): 32-3.
Kirwan, 1995
Kirwan R. The effect of glucocorticoids on
joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council
Low-Dose Glucocorticoid Study Group. N Engl J Med 1995; 333(3): 142-6.
Klintmalm, 1981
Klintmalm GB, Iwatsuki S, Starzl TE.
Cyclosporin A hepatotoxicity in 66 renal allograft recipients. Transplantation
1981; 32(6): 488-9.
Klippel, 1987a
Klippel JH, Austin HA 3d, Balow JE,
LeRiche NG, Steinberg AD, Plotz PH, et al. Studies of immunosuppressive drugs in
the treatment of lupus nephritis. Rheum Dis Clin North Am 1987; 13(1):
47-56.
Klippel, 1987b
Klippel JH. Immunosuppressive therapy. In:
Lahita RG, editor. Systemic lupus erythematosus. New York: John Wiley &
Sons; 1987. p. 923-45.
Klippel, 1998
Klippel JH. Indications for, and use of,
cytotoxic agents in SLE. Baillieres Clin Rheumatol 1998; 12(3): 511-27.
Knysak, 1994
Knysak DJ, McLean JA, Solomon WR, Fox DA,
McCune WJ. Immediate hypersensitivity reaction to cyclophosphamide. Arthritis
Rheum 1994; 37(7): 1101-4.
Koopman, 1998
Koopman WJ, Moreland LW. Rheumatoid
arthritis: anticytokine therapies on the horizon. Ann Int Med 1998; 128(3):
231-3.
Kovarsky, 1983
Kovarsky J. Clinical pharmacology and
toxicology of cyclophosphamide: emphasis on use in rheumatic diseases. Semin
Arthritis Rheum 1983; 12(4): 359-72.
Kraaimaat, 1995
Kraaimaat FW, Van Dam-Baggen RM, Bijlsma
JW. Association of social support and the spouse's reaction with psychological
distress in male and female patients with rheumatoid arthritis. J Rheumatol
1995; 22(4): 644-8.
Kremer, 1992
Kremer JM, Koff R. A debate: should patients
with rheumatoid arthritis on methotrexate undergo lever biopsies? Semin
Arthritis Rheum 1992; 21(6): 376-86.
Kremer, 1994
Kremer JM, Alarcon GS, Lightfoot RW Jr,
Willkens RF, Furst DE, Williams HJ, et al. Methotrexate for rheumatoid
arthritis. Suggested guidelines for monitoring liver toxicity. Arthritis Rheum
1994; 37(3): 316-28.
Kremer, 1995
Kremer JM, Alarcon GS, Alexander RW, Cannon
GW, Weinblatt ME, et al. Methotrexate (MTX)-lung toxicity: clinical features of
thirty-seven cases from seven rheumatology practices. Arthritis Rheum 1995; 38:
S205.
Kyle, 1983.
Kyle RA, Greipp PR. Amyloidosis (AL):
clinical and laboratory features in 229 cases. Mayo Clin Proc 1983; 58(10):
665-83.
Lajas, 2000
Lajas C, Bellajdel B, Abásolo L, Salido M,
Hernández García C, Fernández B, et al. El coste anual de la artritis
reumatoide. Rev Esp Reumatol 2000; 27(5): 206.
Land, 1988
Land W. Cyclosporin in cadaveric renal
transplantation: five year follow-up results of the European Multicentre Trial.
Transplant Proc 1988; 20(3 Suppl 3): 73-7.
Landewé, 1994
Landewé RBM, Goei The HS, van Rijthoven
AWAN, Breedveld FC, Dijkmans BA. A randomized, double blind, 24 week controlled
study of low-dose cyclosporin versus chloroquine for early rheumatoid arthritis.
Arthritis Rheum 1994; 37(5): 637-43.
Landewé, 1996
Landewé RB, Dijkmans BA, van der Woude FJ,
Breedveld FC, Mihatsch MJ, Bruijn JA. Longterm low-dose cyclosporin in patients
with rheumatoid arthritis: renal function loss without structural nephropathy. J
Rheumatol 1996; 23(1): 61-4.
Langevitz, 1992
Langevitz P, Klein L, Pras M, Many A. The
effect of cyclophosphamide pulses on fertility in patients with lupus nephritis.
Am J Reprod Immunol 1992; 28(3-4): 157-8.
Langley, 1984
Langley GB, Sheppeard H. Problems
associated with pain measurement in arthritis: comparison of the visual analogue
and verbal rating scales. Clin Exp Rheumatol 1984; 2(3): 231-4.
Langman, 1999
Langman MJ, Jensen DM, Watson DJ, Harper
SE, Zhao PL, Quan H, et al. Adverse upper gastrointestinal effects of rofecoxib
compared to other NSAIDs. JAMA 1999; 282(20): 1929-33.
Larsen, 1977
Larsen A, Dale K, Eek M. Radiographic
evaluation of rheumatoid arthritis and related conditions by standard reference
films. Acta Radiol Diagn Stockh 1977; 18(4): 481-91.
Larsen, 1995
Larsen A. How to apply Larsen score in
evaluating radiographs of rheumatoid arthritis in longterm studies. J Rheumatol
1995; 22(10): 1974-5.
Lebowitz, 1963
Lebowitz WB. The heart in rheumatoid
arthritis (rheumatoid disease): a clinical and pathological study of sixty-two
cases. Ann Intern Med 1963; 58: 102-23.
Lehmann, 1966
Lehmann JF, Silverman DR, Baum BA, Kirk NL,
Johnston VC. Temperature distributions in the human thigh, produced by infrared,
hot pack and microwave applications. Arch Phys Med Rehab 1966; 47(5): 291-9.
Lin, 1989
Lin HY, Rocher LL, McQuillan MA, Schmaltz S;
Palella TD, Fox IH. Cyclosporin-induced hyperuricemia and gout. N Engl J Med
1989; 321(5): 287-92.
Livneh, 1994
Livneh A, Zemer D, Langevitz P, Laor A,
Sohar E, Pras M. Colchicine treatment of AA amyloidosis of familial
Mediterranean fever: an analysis of factors affecting outcome. Arthritis Rheum
1994; 37(12): 1804-11.
LMSSG, 1999
TNF neutralization in MS: results of a
randomized, placebo-controlled multicenter study. The Lenercept Multiple
Sclerosis Study Group and The University of British Columbia MS/MRI Analysis
Group. Neurology 1999; 53(3): 457-65.
Lockie, 1985
Lockie LM, Smith DM. Forty-seven years
experience with gold therapy in 1019 rheumatoid arthritis patients. Semin
Arthritis Rheum 1985; 14(4): 238-46.
Lohr, 1990
Lohr KN, Rettig RA. Quality of care and
technology assessment: report of a forum of the Council on Health Care
Technology. Institute of Medicine. Washington, DC: National Academy Press,
1990.
Losek, 1981
Losek JD, Werlin SL. Sulphasalazine
hepatotoxicity. Am J Dis Child 1981; 135(11): 1070-2.
Lovat, 1997
Lovat LB, Madhoo S, Pepys MB, Hawkins PN.
Long-term survival in systemic amyloid A amyloidosis complicating Crohn's
disease. Gastroenterology 1997; 112(4): 1362-5.
Love, 1975
Love RR, Sowa JM. Myelomonocytic leukemia
following cyclophosphamide therapy of rheumatoid disease. Ann Rheum Dis 1975;
34(6): 534-5.
Lund, 1983
Lund HI, Nielsen M. Penicillamine-induced
dermatomyositis: a case history. Scand J Rheumatol 1983; 12(4): 350-2.
Maddux, 1986
Maddux MS, Frigo LC, Veremis SA, Pollak R,
Mozes MF. Cyclosporin hepatotoxicity following renal transplantation. Clin
Pharmacol Ther 1986; 39: 208.
Maini, 1998
Maini RN, Breedveld FC, Kalden JR, Smolen JS,
Davis D, McFarlane JD, et al. Therapeutic efficacy of multiple intravenous
infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with
low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;
41(9): 1552-63.
Maini, 1999
Maini R, St Clair EW, Breedveld F, Furst D,
Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor
alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients
receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;
354(9194): 1932-9.
Maksymowych, 1987
Maksymowych W, Russell AS.
Antimalarials in rheumatology: efficacy and safety. Semin Arthritis Rheum 1987;
16(3): 206-21.
Marinos, 1992
Marinos G, Riley J, Painter DM, McCaughan
GW. Sulphasalazine-induced fulminant hepatic failure. J Clin Gastroenterol 1992;
14(2): 132-5.
Masala, 1997
Masala A, Faedda R, Alagna S, Satta A,
Chiarelli G, Rovasio PP, et al. Use of testosterone to prevent
cyclophosphamide-induced azoospermia. Ann Intern Med 1997; 126(4): 292-5.
McCarty, 1995
McCarty DJ, Harman JG, Grassanovich JL,
Qian C, Klein JP. Combination drug therapy of seropositive rheumatoid arthritis.
J Rheumatol 1995; 22:1636-45.
McKendry, 1993
McKendry RJ, Dale P. Adverse effects of
low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 1993; 20(11):
1850-6.
McKendry, 1997
McKendry RJ. The remarkable spectrum of
methotrexate toxicities. Rheum Dis Clin North Am 1997; 23(4): 939-54.
McMahon, 1993
McMahon MJ, Swinson DR, Shettar S,
Wolstenholme R, Chattopadhyay C, Smith P, et al. Bronchiectasis and rheumatoid
arthritis: a clinical study. Ann Rheum Dis 1993; 52(11): 776-9.
Medrano, 1986
Medrano San Ildefonso M, Mauri Llerda JA,
Calabozo Raluy M, Barrio J, Orte Martínez J, Beltrán Gutiérrez J. Panarteritis
nodosa: fibrosis pulmonar después del tratamiento con ciclofosfamida. Rev Esp
Reumatol. 1986; 13(4): 130-2.
Merritt, 1983
Merritt JL, Hunder GG. Passive range of
motion, not isometric exercise, amplifies acute urate synovitis. Arch Phys Med
Rehab 1983; 64(3): 130-1.
Mihats, 1989
Mihats MJ, Thiel G, Ryffel, B Cyclosporin A:
action and side effects. Toxico Lett. 1989; 46: 125-139.
Miller, 1971
Miller JJ 3d, Williams GF, Leissring JC.
Multiple late complications of therapy with cyclophosphamide, including ovarian
destruction. Am J Med 1971; 50(4): 530-5.
Miller, 1993
Miller ST, Flanagan E. The transition from
quality assurance to continuous quality improvement in ambulatory care. QRB Qual
Rev Bull 1993; 19(2): 62-5.
Minor, 1989
Minor MA, Hewett JE, Webel RR, Anderson SK,
Kay DR. Efficacy of physical conditioning in patients with rheumatoid arthritis
and osteoarthritis. Arthritis Rheum 1989; 32(11): 1396-405.
Mladenovic, 1995
Mladenovic V, Domljan Z, Rozman B, Jajic
I, Mihajlovic D, Dordevic J, et al. Safety and effectiveness of leflunomide in
the treatment of patients with active rheumatoid arthritis: results of a
randomized, placebo-controlled, phase II study. Arthritis Rheum 1995; 38(11):
1595-603.
Moder, 1995
Moder KG, Tefferi A, Cohen MD, Menke DM,
Luthra HS. Hematologic malignancies and the use of methotrexate in rheumatoid
arthritis: a retrospective study. Am J Med 1995; 99(3): 276-81.
Moreland, 1997
Moreland LW, Baumgartner SW, Schiff MH,
Tindall EA, Fliischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis
with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.
N Engl J Med 1997; 337(3): 141-7.
Moreland, 1999
Moreland LW, Schiff MH, Baumgartner SW,
Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid
arthritis: a randomized, controlled trial. Ann Intern Med 1999; 130(6):
478-86.
Morgan, 1986
Morgan J, Furst DE. Implications of drug
therapy in the elderly. Clin Rheum Dis 1986; 12(1): 227-44.
Morgan, 1993
Morgan SL, Baggott JE, Alarcon GS.
Methotrexate and sulfasalazine combination therapy: is it worth the risk?
Arthritis Rheum 1993; 36(2): 281-2.
Morris, 1988
Morris PJ. Cyclosporin. In: Morris PJ,
editor. Kidney Transplantation: Principles and Practice. (3 ed). Philadelphia:
Harcourt Brace Jovanovich; 1988. p. 285-317.
Moutsopoulos, 1978
Moutsopoulos HM, Gallagher JD, Decker
JL, Steinberg AD. Herpes zoster in patients with systemic lupus erythematosus
Arthritis Rheum 1978; 21(7): 789-802.
Muller, 1975
Muller W, Pavelka K, Fridrich R. Treatment
of chronic articular effusions with 90-yttrium (90Y). Scand J Rheumatol 1975;
4(4): 216-20.
Munro, 1997
Munro R, Capell HA. Penicillamine. Br J
Rheumatol 1997; 36(1): 104-9.
Myochrysine, 1997
Prod Info Myochrysine® 1997.
Naides, 1995
Naides SJ. Acute parvovirus B19-induced
pancytopenia in the setting of methotrexate therapy for rheumatoid arthritis.
Arthritis Rheum 1995; 38(7): 1023.
Nashel, 1985
Nashel DJ. Mechanisms of action and clinical
applications of cytotoxic drugs in rheumatic disorders. Med Clin North Am 1985;
69(4): 817-40.
Neiman, 1985
Neiman RA, Fye KH. Methotrexate induced
false photosensitivity reaction. J Rheumatol 1985; 12(2): 354-5.
Nicholas, 1988
Nicholas NS, Panayi GS. Rheumatoid
arthritis and pregnancy. Clin Exp Rheumatol 1988; 6(2): 179-82.
Ntoso, 1986
Ntoso KA, Tomaszewski JE, Jimenez SA, Neilson
EG. Penicillamine-induced rapidly progressive glomerulonephritis in patients
with progressive systemic sclerosis: successful treatment of two patients and a
review of the literature. Am J Kidney Dis 1986; 8(3): 159-63.
O´Callaghan, 1986
O'Callaghan JW, Brooks PM.
Disease-modifying agents and immunosuppressive drugs in the elderly. Clin Rheum
Dis 1986; 12(1): 275-89.
O´Dell, 1996
O'Dell JR, Haire CE, Erikson N, Drymalski W,
Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate
alone, sulfasalazine and hydroxychloroquine, or a combination of all three
medications. N Engl J Med 1996; 334(20): 1287-91.
O´Dell, 1997
O’Dell JR. Methotrexate use in rheumatoid
arthritis. Rheum Dis Clin North Am 1997; 23(4): 779-96.
O´Duffy, 1999
O'Duffy EK, Clunie GP, Lui D, Edwards JC,
Ell PJ. Double blind glucocorticoid controlled trial of samarium-153 particulate
hydroxyapatite radiation synovectomy for chronic knee synovitis. Ann Rheum Dis
1999; 58(9): 554-8.
Oates, 1998
Oates JA, Wilkinson GR. Principles of drug
therapy. In: Harrison’s Principles of Internal Medicine (14th ed.). New York:
McGraw-Hill; 1998. p. 411-21.
Ognibene, 1995
Ognibene FP, Shelhamer JH, Hoffman GS,
Kerr GS, Reda D, Fauci AS, et al. Pneumocystis carinii pneumonia: a major
complication of immunosuppressive therapy in patients with Wegener's
granulomatosis. Am J Resp Critical Care Med 1995; 151(3 Pt 1): 795-9.
Okuda, 1994
Okuda Y, Takasugi K, Oyama T, Onuma M, Oyama
H. Amyloidosis in rheumatoid arthritis clinical study of 124 histologically
proven cases. Ryumachi 1994; 34(6): 939-46.
Olson, 1972
Olson JE, Stravino VD. A review of
cryotherapy. Phys Ther 1972; 52(8): 840-53.
OMERACT, 1993
OMERACT, Conference on Outcome Measures in
Rheumatoid Arthritis Clinical Trials. Proceedings. Maastricht, The Netherlands,
April 29-May 3, 1992. J Rheumatol 1993; 20(3): 527-91.
OMERACT, 1994
Reduced joint counts in rheumatoid
arthritis clinical trials. American College of Rheumatology Committee on Outcome
Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1994; 37(4):
463-4.
Onrust, 1998
Onrust SV, Lamb HM. Infliximab: a review of
its use in Crohn's disease and rheumatoid arthritis. BioDrugs 1998; 10(5):
397-422.
OTA, 1988
Office of Technology Assessment. The Quality of
Medical Care: Information for Consumers. Washington, DC: U.S. Government
Printing Office; 1988 June. Report Nº: OTA-H-386.
Oxman, 1991a
Oxman AD, Guyatt GH. Validation of an index
of the quality of review articles. J Clin Epidemiol 1991; 44: 1271-8.
Oxman, 1991b
Oxman AD, Guyatt GH, Singer J, Goldsmith CH,
Hutchison BG, Milner RA, Streiner DL. Agreement among reviewers of review
articles. J Clin Epidemiol 1991; 44: 91-8.
Pai, 1993
Pai S, Helin H, Isomaki H. Frequency of
amyloidosis in Estonian patients with rheumatoid arthritis. Scand J Rheumatol
1993; 22(5): 248-9.
Paimela, 1992
Paimela L. The radiographic criterion in
the 1987 revised criteria for rheumatoid arthritis: reassessment in a
prospective study of early disease. Arthritis Rheum 1992; 35(3): 255-8.
Panayi, 1993
Panayi Gs, Tugwell P. An international
consensus report: the use of cyclosporin A in rheumatoid arthritis. Br J
Rheumatol 1993; 32(Suppl 1): 1-3.
Panayi, 1994
Panayi GS, Tugwell P. The use of cyclosporin
A in rheumatoid arthritis: conclusions of an international review. Br J
Rheumatol 1994; 33(10): 967-9.
Patel, 1976
Patel AR, Shah PC, Rhee HL, Sassoon H, Rao
KP. Cyclophosphamide therapy and interstitial pulmonary fibrosis. Cancer 1976;
38(4): 1542-9.
Paulus, 1984
Paulus HE, Williams HJ, Ward JR, Reading JC,
Egger MJ, Coleman ML, et al. Azathioprine versus D-Penicillamine in rheumatoid
arthritis patients who have been treated unsuccessfully with gold. Arthritis
Rheum 1984; 27(7): 721-7.
Paulus, 1990
Paulus HE, Egger MJ, Ward JR, Williams HJ.
Analysis of improvement in individual rheumatoid arthritis patients treated with
disease-modifying antirheumatic drugs, based on the findings in patients treated
with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group.
Arthritis Rheum 1990; 33(4): 477-84.
Paulus, 1999
Paulus HE, Ramos B, Wong WK, Ahmed A,
Bulpitt K, Park G, et al. Equivalence of the acute phase reactants C-reactive
protein, plasma viscosity, and Westergren erythrocyte sedimentation rate when
used to calculate American College of Rheumatology 20% improvement criteria or
the disease activity score in patients with early rheumatoid arthritis. J
Rheumatol 1999; 26(11): 2324-31.
Pears, 1989
Pears JS, Morley KD. Fatal hypersensitivity
reaction to sulphasalazine. Br J Rheumatol 1989; 28(3): 274-5.
Pease, 1999
Pease CT, Bhakta BB, Devlin J, Emery P. Does
the age of onset of rheumatoid arthritis influence phenotype?: a prospective
study of outcome and prognostic factors. Rheumatology 1999; 38(3): 228-34.
Pedersen-Bjergaard, 1985
Pedersen-Bjergaard J, Ersboll J,
Sorensen HM, Keiding N, Larsen SO, Philip P, et al. Risk of acute nonlymphocytic
leukemia and preleukemia in patients treated with cyclophosphamide for
non-Hodgkin's lymphomas: comparison with results obtained in patients treated
for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann
Intern Med 1985; 103(2): 195-200.
Pedersen-Bjergaard, 1988
Pedersen Bjergaard J, Ersboll J,
Hansen VL, Sorensen BL, Christoffersen K, Hou Jensen K, et al. Carcinoma of the
urinary bladder after treatment with cyclophosphamide for non-Hodgkin´s
lymphoma. N Engl J Med 1988; 318(16): 1028-32.
Penn, 1981
Penn I. Depressed immunity and the development
of cancer. Clin Exp Immunol 1981; 46(3): 459-74.
Pinals, 1981
Pinals RS, Masi AT, Larsen RA. Preliminary
criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981;
24(10): 1308-15.
Pincus, 1983
Pincus T, Summey JA, Soraci SA Jr, Wallston
KA, Hummon NP. Assessment of patient satisfaction in activities of daily living
using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;
26(11): 1346- 53.
Pincus, 1985
Pincus T, Callahan LF. Formal education as a
marker for increased mortality and morbidity in rheumatoid arthritis. J Chronic
Dis 1985; 38(12): 973-84.
Pincus, 1995
Pincus T, Callahan LF, Fuch HA, Larsen A,
Kaye J. Quantitative analysis of hand radiographs in rheumatoid arthritis: time
course of radiographic changes, relation to joint examination measures, and
comparison of different scoring methods. J Rheumatol 1995; 22(10): 1983-9.
Pincus, 1996
Pincus T. Documenting quality management in
rheumatic disease: are patient questionnaires the best (and only) method?
Arthritis Care Res 1996; 9(5): 339-48.
Plotz, 1979
Plotz PH, Klippel JH, Decker JL, Grauman D,
Wolff B, Brown BC, et al. Bladder complications in patients receiving
cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann
Intern Med 1979; 91(2): 221-3.
Prevoo, 1995
Prevoo ML, van’t Hof MA, Kuper HH, van
Leeuwen MA, van de Putte BA, van Riel PL. Modified disease activity scores that
include twenty-eight-joint counts: development and validation in a prospective
longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;
38(1): 44-8.
Prevoo, 1996
Prevoo ML, van Gestel AM, van't Hof MA, van
Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of
patients with rheumatoid arthritis. American Rheumatism Association preliminary
remission criteria in relation to the disease activity score. Br J Rheumatol
1996; 35(11): 1101-5.
Pryor, 1996
Pryor BD, Bologna SG, Kahl LE. Risk factors
for serious infection during treatment with cyclophosphamide and high-dose
corticosteroids for systemic lupus erythematosus. Arthritis Rheum 1996; 39(9):
1475-82.
RACTAG, 1995
The effect of age and renal function on the
efficacy and toxicity of methotrexate in rheumatoid arthritis. Rheumatoid
Arthritis Clinical Trial Archive Group. J Rheumatol 1995; 22(2): 218-23.
Radis, 1995
Radis CD, Kahl LE, Baker GL, Wasko MC, Cash
JM, Gallatin A, et al. Effects of cyclophosphamide on the development of
malignancy and on long-term survival of patients with rheumatoid arthritis: a
20-years follow-up study. Arthritis Rheum 1995; 38(8): 1120-7.
Ramsey-Goldman, 1997
Ramsey-Goldman R, Schilling E.
Immunosuppressive drug use during pregnancy. Rheum Dis Clin North Am 1997;
23(1): 149-67.
Rees, 1991
Rees JH, Woodhead MA, Sheppard MN, Du Bois RM.
Rheumatoid arthritis and cryptogenic organising pneumonitis. Respir Med 1991;
85(3): 243-6.
Reisine, 1998
Reisine S, Fifield J, Winkelman DK.
Employment patterns and their effect on health outcomes among women with
rheumatoid arthritis followed for 7 years. J Rheumatol 1998; 25(10):
1908-16.
Remicade, 1999M
Prod Inf Remicade (TM) 1999. Información
sobre el producto que ofrece el propio laboratorio en una página disponible en
Internet.
Ridaura, 1995
Prod Info Ridaura® 1995.
Riemsma, 1998
Riemsma RP, Rasker JJ, Taal E, Griep EN,
Wouters JM, Wiegman O. Fatigue in rheumatoid arthritis: the role of
self-efficacy and problematic social support. Br J Rheumatol 1998; 37(10):
1042-6.
Ritchie, 1968
Ritchie DM, Boyle JA, McInnes JM, Jasani
MK, Dalakos TG, Grieveson P, et al. Clinical studies with an articular index for
the assessment of joint tenderness in patients with rheumatoid arthritis. Q J
Med 1968; 37(147): 393-406.
Robbins, 1980
Robbins G, McIllmurray MB. Acute renal
failure due to gold. Postgrad Med J 1980 56(655): 366-7.
Rodríguez, 1996
Rodríguez F, Krayenbuhl JC, Harrison WB,
Forre O, Dijkmans BA, Tugwell P, et al. Renal biopsy findings and follow-up of
renal function in rheumatoid arthritis patients treated with cyclosporin A. An
update from the International Kidney Biopsy Registry. Arthritis Rheum 1996;
39(9): 1491-8.
Rodríguez, 1998
Rodríguez de la Serna A. Fármacos
inmunosupresores e inmunoreguladores. In: Pascual Gómez E, Rodríguez Valverde V,
Carbonell Abelló J, Gómez-Reino Carnota JJ, editores. Tratado de Reumatología.
Madrid: Arán Ediciones; 1998. p. 2393-2403.
Roubenoff, 1988
Roubenoff R, Hoyt J, Petri M, Hochberg
MC, Hellmann DB. Effects of antiinflammatory and immunosuppressive drugs on
pregnancy and fertility. Semin Arthritis Rheum 1988; 18(2): 88-110.
Rubenstein, 1990
Rubenstein LV, Kahn KL, Reinisch EJ,
Sherwood MJ, Rogers WH, Kamberg C, et al. Changes in quality of care for five
diseases measured by implicit review, 1981 to 1986. JAMA 1990; 264(15):
1974-9.
Ruymann, 1977
Ruymann FB, Mosijczuk AD, Sayers RJ.
Hepatoma in a child with methotrexate-induced hepatic fibrosis. JAMA 1977;
238(24): 2631-3.
Rynes, 1983
Rynes RI. Ophthalmologic safety of long-term
hydroxychloroquine sulfate treatment. Am J Med 1983; 75(Suppl 1A): 35-9.
Saag, 1997
Saag KG. Low-dose corticosteroid therapy in
rheumatoid arthritis: balancing the evidence. Am J Med 1997; 103(6A):
31S-39S.
Scott, 1989
Scott DL, Dawes PT, Tunn E, et al.
Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis: a
prospective, randomized, placebo-controlled study. Br J Rheumatol 1989;
28:128-33.
Scott, 1992
Scott DL, Panayi GS, van Riel PL, Smolen J,
van de Putte LB. Disease activity in rheumatoid arthritis: preliminary report of
the Consensus Study Group of the European Workshop for Rheumatology Research.
Clin Exp Rheumatol 1992; 10(5): 521-5.
Scott, 1993
Scott DL. A simple index to assess disease
activity in rheumatoid arthritis. J Rheumatol 1993; 20(3): 582-4.
Scott, 2000
Scott DL, Pugner K, Kaarela K, Doyle DV,
Woolf A, Holmes J, et al. The links between joint damage and disability in
rheumatoid arthritis. Rheumatology 2000; 39(2): 122-32.
Scharloo, 1999
Scharloo M, Kaptein AA, Weinman JA, Hazes
JM, Breedveld FC, Rooijmans HG. Predicting functional status in patients with
rheumatoid arthritis. J Rheumatol 1999; 26(8): 1686-93.
Schilsky, 1980
Schilsky RL, Lewis BJ, Sherins RJ, Young
RC. Gonadal dysfunction in patients receiving chemotherapy for cancer. Ann
Intern Med 1980; 93(1): 109-14.
Schnitzer, 1999
Schnitzer TJ, Truitt K, Fleischmann R,
Dalgin P, Block J, Zeng Q, et al. The safety profile, tolerability, and
effective dose range of rofecoxib in the treatment of rheumatoid arthritis:
Phase II Rofecoxib Rheumatoid Arthritis Study Group. Clin Ther 1999; 21(10):
1688-702.
Schur, 1999
Schur PH, Helfgott SM. Evaluation and medical
management of end-stage rheumatoid arthritis. UpToDate 1999 [CD-ROM]. version
7.3.
Segal, 1988
Segal R, Caspi D, Tishler M, Fishel B, Yaron
M. Accelerated nodulosis and vasculitis during methotrexate therapy for
rheumatoid arthritis. Arthritis Rheum 1988; 31(9): 1182-5.
SER, 2000a
Sociedad Española de Reumatología, Sociedad
Española de Medicina Familiar y Comunitaria, Instituto de Salud Carlos III,
Dirección General de Farmacia y Productos Sanitarios. Uso racional de coxibs.
Rev Esp Reumatol 2000; 27: 398-400.
SER, 2000b
Comité de Expertos de la Sociedad Española de
Reumatología. Consenso de la Sociedad Española de Reumatología sobre la terapia
con inhibidores del TNF y otros fármacos inductores de remisión en la artritis
reumatoide. Rev Esp Reumatol 2000; 27(8): 352-4.
Searles, 1987
Searles G, McKendry RJ. Methotrexate
pneumonitis in rheumatoid arthritis: potential risk factors: four case reports
and a review of the literature. J Rheumatol 1987; 14(6): 1164-71.
Shadick. 1994
Shadick NA, Fanta CH, Weinblatt ME,
O'Donnell W, Coblyn JS. Bronchiectasis: a late feature of severe rheumatoid
arthritis. Medicine (Baltimore) 1994; 73(3): 161-70.
Sharp, 1971
Sharp JT, Lidsky MD, Collins LC, Moreland J.
Methods of scoring the progression of radiologic changes in rheumatoid
arthritis: correlation of radiologic, clinical and laboratory abnormalities.
Arthritis Rheum 1971; 14(6): 706-20.
Sharp, 1985
Sharp JT, Young DY, Bluhm GB, Brook A, Brower
AC, Corbett M, et al. How many joints in the hands and wrists should be included
in a score of radiologic abnormalities used to assess rheumatoid arthritis?
Arthritis Rheum 1985; 28(12): 1326-35.
Sharp, 1995
Sharp JT. Assessment of radiographic
abnormalities in rheumatoid arthritis: what have we accomplished and where
should we go from here? J Rheumatol 1995; 22(9): 1787-91.
Sharp, 2000
Sharp JT, Strand V, Leung H, Hurley F,
Loew-Friedrich I. Treatment with leflunomide slows radiographic progression of
rheumatoid arthritis: results from three randomized controlled trials of
leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid
Arthritis Investigators Group. Arthritis Rheum 2000; 43(3): 495-505.
Sherins, 1973
Sherins RJ, De Vita VT. Effect of drug
treatment for lymphoma on male reproductive capacity: studies of men in
remission after therapy. Ann Intern Med. 1973; 79(2): 216-20.
Shiroky, 1991
Shiroky JB, Frost A, Skelton JD, Haegert
DG, Newkirk MM, Neville C. Complications of immunosuppression associated with
weekly low-dose methotrexate. J Rheumatol 1991; 18(8): 1172-5.
Silman, 1988
Silman AJ, Petrie J, Hazleman B, Evans SJ.
Lymphoproliferative cancer and other malignancy in patients with rheumatoid
arthritis treated with azathioprine: a 20 year follow-up study. Ann Rheum Dis
1988; 47(12): 988-92.
Silman, 1993
Silman AJ. Rheumatoid arthritis. In: Silman
AJ, Hochberg MC, editors. Epidemiology of the rheumatic diseases. Oxford: Oxford
University Press; 1993.
Simon, 1999
Simon LS, Weaver AL, Graham DY, Kivitz AJ,
Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal
effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
JAMA 1999; 282(20): 1921-8.
Singh, 1989
Singh G, Fries JF, Spitz P, Williams CA.
Toxic effects of azathioprine in rheumatoid arthritis. A national post-marketing
perspective. Arthritis Rheum 1989; 32(7): 837-43.
Sledge, 1984
Sledge CB, Atcher RW, Shortkroff S, Anderson
RJ, Bloomer WD, Hurson BJ. Intra-articular radiation synovectomy. Clin Orthop
1984; (182): 37-40.
Sledge, 1986
Sledge CB, Zuckerman JD, Zalutsky MR, Atcher
RW, Shortkroff S, Lionberger DR, et al. Treatment of rheumatoid synovitis of the
knee with intraarticular injection of dysprosium 165-ferric hydroxide
macroaggregates. Arthritis Rheum 1986; 29(2): 153-9.
Sledge, 1987
Sledge CB, Zuckerman JD, Shortkroff S,
Zalutsky MR, Venkatesan P, Snyder MA, et al. Synovectomy of the rheumatoid knee
using intra-articular injection of dysprosium-165-ferric hydroxide
macroaggregates. J Bone Joint Surg Am 1987; 69(7): 970-5.
Smolen, 1999
Smolen JS, Kalden JR, Scott DL, Rozman B,
Kvien TK, Larsen A, et al. Efficacy and safety of leflunomide compared with
placebo and sulphasalazine in active rheumatoid arthritis: a double-blind,
randomized, multicentre trial. Lancet 1999; 353(9149): 259-66.
Songsiridej, 1990
Songsiridej N, Furst DE. Methotrexate:
the rapidly acting drug. Baillieres Clin Rheumatol 1990; 4(3): 575-93.
Spiegel, 1986
Spiegel JS, Spiegel TM, Ward NB, Paulus HE,
Leake B, Kane RL. Rehabilitation in rheumatoid arthritis patients: a controlled
trial. Arthritis Rheum 1986; 29(5): 628-37.
Stein, 1997
Stein CM, Pincus T, Yocum D. Combination
treatment of severe rheumatoid arthritis with cyclosporin and methotrexate for
forty-eight weeks: an open-label extension study. The Methotrexate-Cyclosporin
Combination Study Group. Arthritis Rheum 1997; 40:1843-51.
Stein, 1980
Stein HB, Patterson AC, Offer RC, Atkins CJ,
Teufel A, Robinson HS, et al. Adverse effects of D-penicillamine in rheumatoid
arthritis. Ann Intern Med 1980; 92(1): 24-9.
Steinberg, 1981
Steinberg AD. Immunoregulatory agents.
In: Kelley WN, Harris ED, Ruddy S and Sledge CB, editors. Textbook of
rheumatology. Philadelphia: Saunders WB; 1981. p. 841-61.
Strand, 1999
Strand V, Cohen S, Schiff M, Weaver A,
Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with
leflunomide compared with placebo and methotrexate. Arch Intern Med 1999;
159(21): 2542-50.
Sutej, 1991
Sutej PG, Hadler NM. Current principles of
rehabilitation for patients with rheumatoid arthritis. Clin Orthop.1991; (265):
116-24.
Sznol, 1987
Sznol M, Ohnuma T, Holland JF. Hepatotoxicity
of drugs used for hematologic neoplasia. Semin Liver Dis 1987; 7(3): 237-56.
Taggart, 1987
Taggart AJ, Hill J, Astbury C, Dixon JS,
Bird HA, Wright V. Sulphasalazine alone or in combination with D-penicillamine
in rheumatoid arthritis. Br J Rheumatol 1987; 26:32-6.
Tan, 1995
Tan SY, Pepys MB, Hawkins PN. Treatment of
amyloidosis. Am J Kidney Dis 1995; 26(2): 267-85.
Taylor, 1981
Taylor PG, Cumming DC, Coreenblum B.
Successful treatment of D-penicillamine-induced breast gigantism with danazol.
Br Med J 1981; 282(6261): 362-3.
Thrasher, 1990.
Thrasher JB, Miller GJ, Wettlaufer JN.
Bladder leiomyosarcoma following cyclophosphamide therapy for lupus nephritis. J
Urol 1990; 143(1): 119-21.
Thurtle, 1983
Thurtle OA, Cawley MI. The frequency of leg
ulceration in rheumatoid arthritis: a survey. J Rheumatol 1983; 10(3):
507-9.
Tindall, 1987
Tindall RS, Rollins JA, Phillips JT,
Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind,
randomized, placebo-controlled trial of cyclosporin in myasthenia gravis. N Engl
J Med 1987; 316(12): 719-24.
Toovey, 1981
Toovey S, Hudson E, Hendry WF, Levi AJ.
Sulphasalazine and male infertility: reversibility and possible mechanism. Gut
1981; 22(6): 445-51.
Tornero, 1998
Tornero Molina J, Fernández Echevarría JA,
Vidal Fuentes J. Repercusión socioeconómica de la invalidez permanente por
enfermedad reumática en la provincia de Guadalajara. Rev Esp Reumatol 1998;
25(9): 346-51.
Townes, 1976
Townes AS, Sowa JM, Shulman LE. Controlled
trial of cyclophosphamide in rheumatoid arthritis. Arthritis Rheum 1976; 19(3):
563-73.
Trompeter, 1981
Trompeter RS, Evans PR, Barratt TM.
Gonadal function in boys with steroid-responsive nephrotic syndrome treated with
cyclophosphamide for short periods. Lancet 1981; 1(8231): 1177-9.
Tsakonas, 2000
Tsakonas E, Fitzgerald AA, Fitzcharles MA,
Cividino A, Thorne JC, M'Seffar A, et al. Consequences of delayed therapy with
second-line agents in rheumatoid arthritis: a 3 year follow-up on the
hydroxychloroquine in early rheumatoid arthritis (HERA) study. J Rheumatol 2000;
27(3): 623-9.
Tugwell, 1990
Tugwell P, Bombardier C, Gent M, Ho M,
Iwatsuki S, Griffith BP. Low-dose cyclosporin versus placebo in patients with
rheumatoid arthritis. Lancet 1990; 335(8697): 1051-5.
Tugwell, 1993
Tugwell P, Boers M. Developing consensus on
preliminary core efficacy endpoints for rheumatoid arthritis clinical trials.
OMERACT Committee. J Rheumatol 1993; 20(3): 555-6.
Tugwell, 1995a
Tugwell P. International consensus
recommendations on cyclosporin use in rheumatoid arthritis. Drugs 1995; 50(Suppl
1): 48-56.
Tugwell, 1995b
Tugwell P, Pincus T, Yocum D, Stein M,
Gluck O, Kraag G, et al. Combination therapy with cyclosporin and methotrexate
in severe rheumatoid arthritis. N Engl J Med 1995; 333(3): 137-41.
Van der Heijde, 1990
Van der Heijde DM, van't Hof MA, van
Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al., Judging disease
activity in clinical practice in rheumatoid arthritis: first step in the
development of a disease activity score. Ann Rheum Dis 1990; 49(11): 916-20.
Van der Heijde, 1992a
Van der Heijde DM, van't Hof MA,
van Riel PL, van Leeuwen MA, van Rijswijk MH, van de Putte LB. Validity of
single variables and composite indices for measuring disease activity in
rheumatoid arthritis. Ann Rheum Dis 1992; 51(2): 177-81.
Van der Heijde, 1992b
Van der Heijde DMFM, van Leeuwen
MA, van Riel PL, Koster AM, van't Hof MA, van Rijswijk MH, et al. Biannual
radiographic assessments of hands and feet in a three-year prospective followup
of patients with early rheumatoid arthritis. Arthritis Rheum 1992; 35(1):
26-34.
Van der Heijde, 1994
Van der Heijde A, Jacobs JW, van
Albada-Kuipers GA, Kraaimaat FW, Geenen R, Bijlsma JW. Physical disability and
psychological well being in recent onset rheumatoid arthritis. J Rheumatol 1994;
21(1): 28-32.
Van der Heijde, 1995a
Van der Heijde A, Remme CA, Hofman
DM, Jacobs JWG, Bijlsma JWJ. Prediction of progression of radiologic damage in
newly diagnosed rheumatoid arthritis. Arthritis Rheum 1995; 38(10): 1466-74.
Van der Heijde, 1995b
Van der Heijde DM. Joint erosions
and patients with early rheumatoid arthritis. Br J Rheumatol 1995; 34(Suppl 2):
74-8.
Van der Heijde, 1998
Van der Heijde DM, Jacobs JW. The
original "DAS" and the "DAS28" are not interchangeable: comment on the articles
by Prevoo et al. Arthritis Rheum 1998; 41(5): 942-5.
Van der Heijde, 1999
Van der Heijde D. Boers M, Lassere
M. Methodological issues in radiographic scoring methods in rheumatoid
arthritis. J Rheumatol 1999; 26(3): 726-30.
Van Gestel, 1995
Van Gestel AM, Laan RF, Haagsma CJ, van
de Putte LBA, van Riel PLCM. Oral steroids as bridge therapy in rheumatoid
arthritis patients starting with parenteral gold: a randomized double-blind
placebo-controlled trial. Br J Rheumatol 1995; 34(4): 347-51.
Van Gestel, 1996
Van Gestel AM, Prevoo ML, van't Hof MA,
van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the
European League Against Rheumatism response criteria for rheumatoid arthritis.
Comparison with the preliminary American College of Rheumatology and the World
Health Organization/International League Against Rheumatism Criteria. Arthritis
Rheum 1996; 39(1): 34-40.
Van Gestel, 1998
Van Gestel AM, Haagsma CJ, van Riel
PLCM. Validation of rheumatoid arthritis improvement criteria that included
simplified joint counts. Arthritis Rheum 1998; 41(10): 1845-50.
Van Gestel, 1999
Van Gestel AM, Anderson JJ, van Riel PL,
Boers M, Haagsma CJ, Rich B, et al. ACR and EULAR improvement criteria have
comparable validity in rheumatoid arthritis trials. J Rheumatol 1999; 26(3):
705-11.
Van Leeuwen, 1993
Van Leeuwen MA, van Rijswijk MH, van
der Heijde DM, Te Meerman GJ, van Riel PL, Houtman PM, et al. The acute-phase
response in relation to radiographic progression in early rheumatoid arthritis.
A prospective study during the first three years of the disease. Br J Rheumatol
1993; 32(Suppl 3): 9-13.
Van Leeuwen, 1997
Van Leeuwen MA, van Rijswijk MH,
Sluiter WJ, van Riel PL, Kuper IH, van de Putte LB et al. Individual
relationship between progression of radiological damage and the acute phase
response in early rheumatoid arthritis: towards development of a decision
support system. J Rheumatol 1997; 24(1): 20-7.
Van Riel, 1992
Van Riel PL. Provisional guidelines for
measuring disease activity in clinical trials on rheumatoid arthritis. Br J
Rheumatol 1992; 31(12): 793-4.
Van Rijthoven, 1991
Van Rijthoven AW, Dijkmans BAC, Goei
The HS, Meijers KA, Montnor Beckers ZL, Moolenburgh JD, et al. Comparison of
cyclosporin and D-penicillamine for rheumatoid arthritis: a randomized, double
blind, multicentre study. J Rheumatol 1991; 18(6): 815-20.
Van Zeben, 1992
Van Zeben D, Hazes JM, Zwinderman AH,
Cats A, van der Voort EA, Breedveld FC. Clinical significance of rheumatoid
factors in early rheumatoid arthritis: results of a follow-up study. Ann Rheum
Dis 1992; 51(9): 1029-35.
Villaverde, 2000
Villaverde V, Hernández C, Fernández
Sueiro JL, Hernández A, Graña J, Carmona L. Prevalencia de la artritis
reumatoide en la población española. Rev Esp Reumatol 2000; 27(5): 157.
Vollertsen, 1986
Vollertsen RS, Conn DL, Ballard DJ,
Ilstrup DM, Kazmar RE, Silverfield JC. Rheumatoid vasculitis: survival and
associated risk factors. Medicine (Baltimore) 1986; 65(6): 365-75.
Vyse, 1992
Vyse T, So AK Sulphasalazine induced
autoimmune syndrome. Br J Rheumatol 1992; 31(2): 115-6.
Wakefield, 2000
Wakefield RJ, Gibbon WW, Conaghan PG,
O’Connor P, McGonagle D, Pease C, et al. The value of sonography in the
detection of bone erosions in patients with rheumatoid arthritis: a comparison
with conventional radiography. Arthritis Rheum 2000; 43(12): 2762-70.
Waldman, 1998
Waldman BJ, Figgie MP. Indications,
technique, and results of total shoulder arthroplasty in rheumatoid arthritis.
Orthop Clin North Am 1988; 29(3): 435-44.
Walker, 1993
Walker AM, Funch D, Dreyer NA, Tolman KG,
Kremer JM, Alarcon GS, et al. Determinants of serious liver disease among
patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis
Rheum 1993; 36(3): 329-35.
Wall, 1975
Wall RL, Clausen KP. Carcinoma of the urinary
bladder in patients receiving cyclophosphamide. N Engl J Med 1975; 293(6):
271-3.
Warne, 1973
Warne GL, Fairley KF, Hobbs JB, Martin FI.
Cyclophosphamide-induced ovarian failure. N Engl J Med 1973; 289(22):
1159-62.
Wang, 1995
Wang CL, Wang F, Bosco JJ. Ovarian failure in
oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus 1995;
4(1): 11-4.
Ward, 1983
Ward JR, Williams HJ, Egger MJ, Reading JC,
Boyce E, Altz Smith M, et al. Comparison of auranofin, gold sodium thiomalate,
and placebo in the treatment of rheumatoid arthritis: a controlled clinical
trial. Arthritis Rheum 1983; 26(11): 1303-15.
Weinblatt, 1999a
Weinblatt ME, Kremer JM, Bankhurst AD,
Bulpitt KJ, Fleischmann RM, Fox IR, et al. A trial of etanercept, a recombinant
tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid
arthritis receiving methotrexate. N Engl J Med 1999; 340(4): 253-9.
Weinblatt, 1999b
Weinblatt ME, Kremer JM, Coblyn JS,
Maier AL, Helfgott SM, Morrell M, et al. Pharmacokinetics, safety, and efficacy
of treatment with methotrexate and leflunomide in patients with active
rheumatoid arthritis. Arthritis Rheum 1999; 42(7): 1322-8.
Weinstein, 1985
Weinstein A, Utsinger PD.
Immunoregulatory drugs In: Utsinger PD, Zvaifler NJ, Ehrlich GE, editors.
Rheumatoid Arthritis. Philadelphia: Lippincott JB Company; 1985. p. 635-44.
Weiss, 1989
Weiss MM: Corticosteroids in rheumatoid
arthritis. Semin Arthritis Rheum 1989;19(1): 9-21.
West, 1997
West SG. Methotrexate hepatotoxicity. Rheum
Dis Clin North Am 1997; 23(4): 883-915.
Wheeler, 1981
Wheeler GE. Cyclophosphamide-associated
leukemia in Wegener's granulomatosis. Ann Intern Med 1981; 94(3): 361-2.
White, 1989
White DA, Rankin JA, Stover DE, Gellene RA,
Gupta S. Methotrexate pneumonitis: bronchoalveolar lavage findings suggest an
immunologic disorder. Am Rev Resp Dis 1989; 139(1): 18-21.
Willemsen, 1990
Willemsen MJ, De Coninck AL, De Raeve LE,
Roseeuw DI. Penicillamine-induced pemphigus erythematosus. Int J Dermatol 1990;
29(3): 193-7.
Williams, 1983
Williams HJ, Ward JR, Reading JC, Egger
MJ, Grandone JT, Samuelson CO, et al. Low-dose D-penicillamine therapy in
rheumatoid arthritis: a controlled, double-blind clinical trial. Arthritis Rheum
1983; 26(5): 581-92.
Williams, 1988
Williams HJ, Ward JR, Dahl SL, Clegg DO,
Willkens RF, Oglesby T, et al. A controlled trial comparing sulfasalazine, gold
sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum 1988;
31(6): 702-13.
Williams, 1992
Williams HJ, Ward JR, Reading JC, Brooks
RH, Clegg DO, Skosey JL, et al. Comparison of auranofin, methotrexate, and the
combination of both in the treatment of rheumatoid arthritis. A controlled
clinical trial. Arthritis Rheum 1992; 35:259-69.
Willkens, 1995
Willkens RF, Sharp JT, Stablein D, Marks
C, Wortmann R. Comparison of azathioprine, methotrexate, and the combination of
the two in the treatment of rheumatoid arthritis. A forty-eight-week controlled
clinical trial with radiologic outcome assessment. Arthritis Rheum 1995;
38:1799-806.
Wilske, 1989
Wilske KR, Healey LA. Remodeling the pyramid
- a concept whose time has come. J Rheumatol 1989; 16:565-7.
Wolfe, 1985
Wolfe F, Hawley DJ. Remission in rheumatoid
arthritis. J Rheumatol 1985;12(2): 245-52.
Wolfe, 1991
Wolfe F, Cathey MA. The assessment and
prediction of functional disability in rheumatoid arthritis. J Rheumatol 1991;
18(9): 1298-306.
Wolfe, 1998
Wolfe F, Hawley DJ. The longterm outcomes of
rheumatoid arthritis: Work disability. A prospective 18 year study of 823
patients. J Rheumatol 1998; 25(11): 2108-17.
Wolfe, 1999a
Wolfe F, Pincus T. Listening to the patient:
a practical guide to self-report questionnaires in clinical care. Arthritis
Rheum 1999; 42(9): 1797-808.
Wolfe, 1999b
Wolfe F, Lassere M, van der Heijde D, Stucki
G, Suarez Almazor M, Pincus T, et al. Preliminary core set of domains and
reporting requirements for longitudinal observational studies in rheumatology. J
Rheumatol 1999; 26(2): 484-9.
Worth, 1971
Worth PH. Cyclophosphamide and the bladder.
Br Med J 1971; 3(767): 182.
Worthley, 1995
Worthley SG, McNeil JD.
Leukoencephalopathy in a patient taking low dose oral methotrexate therapy for
rheumatoid arthritis. J Rheumatol 1995; 22(2): 335-7.
Yuh, 1995
Yuh DD, Gandy KL, Morris RE, Hoyt G, Gutierrez
J, Reitz BA, et al. Leflunomide prolongs pulmonary allograft and xenograft
survival. J Heart Lung Transplant 1995; 14(6 Pt 1): 1136-44.
Zemer, 1986
Zemer D, Pras M, Sohar E, Modan M, Cabili S,
Gafni J. Colchicine in the prevention and treatment of the amyloidosis of
familial Mediterranean fever. N Engl J Med 1986; 314(16): 1001-5.
SR1. |
Suarez Almazor ME, Spooner CH, Belseck E, Shea B. Auranofin versus placebo in rheumatoid arthritis. Cochrane Database Syst Rev 2000; (2): CD002048. |
SR2. |
Suarez Almazor ME, Spooner C, Belseck E. Azathioprine for rheumatoid arthritis. Cochrane Database Syst Rev 2000; (2): CD001461. |
SR3. |
Suarez Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Cyclophosphamide for rheumatoid arthritis. Cochrane Database Syst Rev 2000; (2): CD001157. |
SR4. |
Wells G, Haguenauer D, Shea B, Suarez Almazor ME, Welch VA, Tugwell P. Cyclosporin for rheumatoid arthritis. Cochrane Database Syst Rev 2000; (2): CD001083. |
SR5. |
Suarez Almazor ME, Spooner C, Belseck E. Penicillamine for rheumatoid arthritis. Cochrane Database Syst Rev 2000; (2): CD001460. |
SR6. |
Suarez Almazor ME, Belseck E, Shea B, Homik J, Wells G, Tugwell P. Antimalarials for rheumatoid arthritis. Cochrane Database Syst Rev 2000; (2): CD000959. |
SR7. |
Suarez Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Methotrexate for rheumatoid arthritis. Cochrane Database Syst Rev 2000; (2): CD000957. |
SR8. |
Clark P, Tugwell P, Bennet K, Bombardier C, Shea B, Wells G, Suarez Almazor ME. Injectable gold for rheumatoid arthritis. Cochrane Database Syst Rev 2000; (2): CD000520. |
SR9. |
Suarez Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Sulfasalazine for rheumatoid arthritis. Cochrane Database Syst Rev 2000; (2): CD000958. |
Complement of 21 | |
C1. |
Weinblatt ME, Polisson R, Blotner SD, Sosman JL, Aliabadi P, Baker N, et al. The effects of drug therapy on radiographic progression of rheumatoid arthritis: results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis Rheum 1993; 36(5): 613-9. |
Complement of 22 | |
C2. |
Lopez-Mendez A, Daniel WW, Reading JC, Ward JR, Alarcon GS. Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate, auranofin, or a combination of the two. Arthritis Rheum 1993; 36(10): 1364-9. |
Complement of 30 | |
C3. |
Ward JR, Williams HJ, Boyce E, Egger MJ, Reading JC, Samuelson CO. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis: subsets of responses. Am J Med 1983; 75(6A): 133-7. |
Complement of 33 | |
C4. |
Davis P, Menard H, Thompson J, Harth M, Beaudet F. One-year comparative study of gold sodium thiomalate and auranofin in the treatment of rheumatoid arthritis. J Rheumatol 1985; 12(1): 60-7. |
Complement of 37 | |
C5. |
Van Riel PLCM, Larsen A, Van de Putte LBA, Gribnau FWJ. Effects of aurothioglucose and auranofin on radiographic progression in rheumatoid arthritis. Clin Rheumatol 1986; 5(3): 359-64. |
Complement of 39 | |
C6. |
Schattenkirchner M, Kaik B, Muller-Fassbender H, Rau R, Zeidler H. Auranofin and sodium aurothiomalate in the treatment of rheumatoid arthritis: a double-blind, comparative multicenter study. J Rheumatol Suppl 1982; 8: 184-9. |
Complement of 47 | |
C7. |
Rau R, Herborn G, Menninger H, Sangha O. Progression in early erosive rheumatoid arthritis: 12 month results from a randomized controlled trial comparing methotrexate and gold sodium thiomalate. Br J Rheumatol 1998; 37(11): 1220-6. |
C8. |
Rau R, Herborn G, Menninger H, Blechschmidt J. Comparison of intramuscular methotrexate and gold sodium thiomalate in the treatment of early erosive rheumatoid arthritis: 12 month data of a double-blind parallel study of 174 patients. Br J Rheumatol 1997; 36(3): 342-52. |
Complement of 49 | |
C9. |
Porter D, Madhok R, Hunter JA, Capell HA. Prospective trial comparing the use of sulphasalazine and auranofin as second line drugs in patients with rheumatoid arthritis. Ann Rheum Dis 1992; 51(4): 461-4. |
Complement of 50 | |
C10. |
Capell HA, Marabani M, Madhok R, Torley H, Hunter JA. Degree and extent of response to sulphasalazine or penicillamine therapy for rheumatoid arthritis: results from a routine clinical environment over a two-year period. Q J Med 1990; 75(276): 335-44. |
Complement of 52 | |
C.11. |
Heijde DM, Riel PL, Nuver-Zwart IH, Gribnau FW, Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989; 1(8646): 1036-8. |
C12. |
Van der Heijde DM, Van Riel PLCM, Van de Putte LBA. Sensitivity of a Dutch Health Assessment Questionnaire in a trial comparing hydroxychloroquine vs sulphasalazine. Scand J Rheumatol 1990; 19(6): 407-12. |
Redundant with 1 | |
R1. |
Woodland J, Mason RM, Harris J, Dixon AS, Currey HL, Brownjohn AM, et al. Trial of azathioprine, cyclophosphamide, and gold in rheumatoid arthritis. Ann Rheum Dis 1974; 33(4): 399-401. |
Redundant with 7 | |
R2. |
Berry H, Liyanage S, Durance R, Barnes CG, Berger L. Trial comparing azathioprine and penicillamine in treatment of rheumatoid arthritis. Ann Rheum Dis 1976; 35(6): 542-3. |
Redundant with 19 | |
R3. |
Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C, et al. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42(9): 1870-8. |
Redundant with 24 | |
R4. |
Jeurissen MEC, Boerbooms AMT, Van de Putte LBA, Doesburg WH, Lemmens AM. Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis: a randomized, double-blind study. Arch Intern Med 1991; 114: 999-1004. |
R5. |
Kerstens PJSM, Boerbooms AMT, Jeurissen MEC, Westgeest TAA, Van Erp A, Mulder J, et al. Antiperinuclear factor and disease activity in rheumatoid arthritis: longitudinal evaluation during methotrexate and azathioprine therapy. J Rheumatol 1994; 21(12): 2190-4. |
Redundant with 25 | |
R6. |
Willkens RF, Stablein D. Combination treatment of rheumatoid arthritis using azathioprine and methotrexate: a 48-week controlled clinical trial. J Rheumatol 1996; 23(Suppl 44): 64-8. |
R7. |
Willkens RF, Urowitz MB, Stablein DM, McKendry RJR, Berger RG, Box JH, et al. Comparison of azathioprine, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1992; 35(8): 849-56. |
Redundant with 30 | |
R8. |
Williams HJ, Ward JR, Egger MJ, Reading JC, Samuelson CO, Altz-Smith M, et al. Auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis: cooperative systematic studies of rheumatic diseases. Clin Rheumatol 1984; 3(suppl.1): 39-50. |
R9. |
Williams HJ, Ward JR. Comparison of oral and parenteral gold therapy and placebo in the treatment of rheumatoid arthritis. Scand J Rheumatol Suppl 1983; 51: 92-9. |
Redundant with 39 | |
R10. |
Schattenkirchner M, Bröll H, Kaik B, M¨ller-Fassbender H, Rau R, Zeidler H. Auranofin and gold sodium thiomalate in the treatment of rheumatoid arthritis: a one-year, double-blind, comparative multicenter study. Klin Wochenschr 1988; 66(4): 167-74. |
Redundant with 41 | |
R11. |
Huskisson EC, Gibson TJ, Wykeham Balme H, Berry H, Burry HC, Grahame R, et al. Penicillamine or gold for rheumatoid arthritis?: multicentre trial using 'blind' observers: the first six months. Ann Rheum Dis 1974; 33(4): 399. |
Redundant with 52 | |
R12. |
Van der Heijde DMFM, Van Riel PLCM, Nuwer-Zwart IH, Van de Putte LBA. Alternative methods for analysis of radiographic damage in a randomized, double blind, parallel group clinical trial comparing hydroxychloroquine and sulfasalazine. J Rheumatol 2000; 27(2): 535-8. |
Redundant with 63 | |
R13. |
Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354(9194): 1932-9. |
Copyright: All copyrights reserved by the Spanish Society of Rheumatology.